Hubbry Logo
Centers for Disease Control and PreventionCenters for Disease Control and PreventionMain
Open search
Centers for Disease Control and Prevention
Community hub
Centers for Disease Control and Prevention
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Centers for Disease Control and Prevention
Centers for Disease Control and Prevention
from Wikipedia

Centers for Disease Control and Prevention
Centers for Disease Control and Prevention logo
Map
Agency overview
FormedJuly 1, 1946; 79 years ago (1946-07-01)
Preceding agencies
  • Office of National Defense Malaria Control Activities (1942)
  • Office of Malaria Control in War Areas (1942–46)
  • Communicable Disease Center (1946–67)
  • National Communicable Disease Center (1967–70)
  • Center for Disease Control (1970–80)
  • Centers for Disease Control (1980–92)
JurisdictionFederal government of the United States
HeadquartersAtlanta, Georgia, U.S.
33°47′58″N 84°19′42″W / 33.79944°N 84.32833°W / 33.79944; -84.32833
Employees11,814 Edit this on Wikidata[1]
Annual budgetUS$11.581 billion (FY24)
Agency executive
Parent agencyUnited States Department of Health and Human Services
Websitewww.cdc.gov Edit this at Wikidata

The Centers for Disease Control and Prevention (CDC) is the national public health agency of the United States. It is a United States federal agency under the Department of Health and Human Services (HHS), and is headquartered in Atlanta, Georgia.[2][3]

The agency's main goal is the protection of public health and safety through the control and prevention of disease, injury, and disability in the US and worldwide.[4] The CDC focuses national attention on developing and applying disease control and prevention. It especially focuses its attention on infectious disease, food borne pathogens, environmental health, occupational safety and health, health promotion, injury prevention, and educational activities designed to improve the health of United States citizens. The CDC also conducts research and provides information on non-infectious diseases, such as obesity and diabetes, and is a founding member of the International Association of National Public Health Institutes.[5]

As part of the announced 2025 HHS reorganization, CDC is planned to be reoriented towards infectious disease programs. It is planned to absorb the Administration for Strategic Preparedness and Response, while the National Institute for Occupational Safety and Health is planned to move into the new Administration for a Healthy America.[6]

History

[edit]

Establishment

[edit]

The Communicable Disease Center was founded July 1, 1946, as the successor to the World War II Malaria Control in War Areas program[7] of the Office of National Defense Malaria Control Activities.[8]

Preceding its founding, organizations with global influence in malaria control were the Malaria Commission of the League of Nations and the Rockefeller Foundation.[9] The Rockefeller Foundation greatly supported malaria control,[9] sought to have the governments take over some of its efforts, and collaborated with the agency.[10]

The new agency was a branch of the U.S. Public Health Service and Atlanta was chosen as the location because malaria was endemic in the Southern United States.[11] The agency changed names before adopting the name Communicable Disease Center in 1946. Offices were located on the sixth floor of the Volunteer Building on Peachtree Street.[12]

With a budget at the time of about $1 million, 59 percent of its personnel were engaged in mosquito abatement and habitat control with the objective of control and eradication of malaria in the United States.[13]

Among its 369 employees, the main jobs at CDC were originally entomology and engineering. In CDC's initial years, more than six and a half million homes were sprayed, mostly with DDT. In 1946, there were only seven medical officers on duty and an early organization chart was drawn. Under Joseph Walter Mountin, the CDC continued to be an advocate for public health issues and pushed to extend its responsibilities to many other communicable diseases.[14]

In 1947, the CDC made a token payment of $10 to Emory University for 15 acres (61,000 m2) of land on Clifton Road in DeKalb County, still the home of CDC headquarters as of 2025. CDC employees collected the money to make the purchase. The benefactor behind the "gift" was Robert W. Woodruff, chairman of the board of the Coca-Cola Company. Woodruff had a long-time interest in malaria control, which had been a problem in areas where he went hunting. The same year, the PHS transferred its San Francisco based plague laboratory into the CDC as the Epidemiology Division, and a new Veterinary Diseases Division was established.[7]

The CDC inherited the Tuskegee syphilis experiment from its predecessor, the U.S. Public Health Service.[15] In the study, which lasted from 1932 to 1972, a group of Black men (nearly 400 of whom had syphilis) were studied to learn more about the disease. The disease was left untreated in the men, who had not given their informed consent to serve as research subjects.[15]

Growth

[edit]
The Communicable Disease Center moved to its current headquarters in 1960. Building 1 is pictured in 1963.

In 1951, Chief Epidemiologist Alexander Langmuir's warnings of potential biological warfare during the Korean War spurred the creation of the Epidemic Intelligence Service (EIS) as a two-year postgraduate training program in epidemiology. The success of the EIS program led to the launch of Field Epidemiology Training Programs (FETP) in 1980, training more than 18,000 disease detectives in over 80 countries.[16] In 2020, FETP celebrated the 40th anniversary of the CDC's support for Thailand's Field Epidemiology Training Program. Thailand was the first FETP site created outside of North America and is found in numerous countries, reflecting CDC's influence in promoting this model internationally.[17] The Training Programs in Epidemiology and Public Health Interventions Network (TEPHINET) has graduated 950 students.[18]

The mission of the CDC expanded beyond its original focus on malaria to include sexually transmitted diseases when the Venereal Disease Division of the U.S. Public Health Service (PHS) was transferred to the CDC in 1957. Shortly thereafter, Tuberculosis Control was transferred (in 1960) to the CDC from PHS, and then in 1963 the Immunization program was established.[19]

It became the National Communicable Disease Center effective July 1, 1967, and the Center for Disease Control on June 24, 1970. At the end of the Public Health Service reorganizations of 1966–1973, it was promoted to being a principal operating agency of PHS.[8]

1980–2018

[edit]
Arlen Specter Headquarters and Emergency Operations Center

The organization was renamed to the plural Centers for Disease Control effective October 14, 1980,[8] as the modern organization of having multiple constituent centers was established. By 1990, it had four centers formed in the 1980s: the Center for Infectious Diseases, Center for Chronic Disease Prevention and Health Promotion, the Center for Environmental Health and Injury Control, and the Center for Prevention Services; as well as two centers that had been absorbed by CDC from outside: the National Institute for Occupational Safety and Health in 1973, and the National Center for Health Statistics in 1987.[20]

An act of the United States Congress appended the words "and Prevention" to the name effective October 27, 1992. However, Congress directed that the initialism CDC be retained because of its name recognition.[21] Since the 1990s, the CDC focus has broadened to include chronic diseases, disabilities, injury control, workplace hazards, environmental health threats, and terrorism preparedness. CDC combats emerging diseases and other health risks, including birth defects, West Nile virus, obesity, avian, swine, and pandemic flu, E. coli, and bioterrorism, to name a few. The organization would also prove to be an important factor in preventing the abuse of penicillin. In May 1994 the CDC admitted having sent samples of communicable diseases to the Iraqi government from 1984 through 1989 which were subsequently repurposed for biological warfare, including Botulinum toxin, West Nile virus, Yersinia pestis and Dengue fever virus.[22]

In 1992, Mark L. Rosenberg and five CDC colleagues founded the CDC's National Center for Injury Prevention and Control, with an annual budget of approximately $260,000. They focused on "identifying causes of firearm deaths, and methods to prevent them".[23] Their first report, published in the New England Journal of Medicine in 1993 entitled "Guns are a Risk Factor for Homicide in the Home", reported "mere presence of a gun in a home increased the risk of a firearm-related death by 2.7 percent, and suicide fivefold – a "huge" increase".[23] In response, the National Rifle Association of America launched a "campaign to shut down the Injury Center". Two conservative pro-gun groups, Doctors for Responsible Gun Ownership and Doctors for Integrity and Policy Research joined the pro-gun effort, and, by 1995, politicians also supported the pro-gun initiative. In 1996, Jay Dickey (R) Arkansas introduced the Dickey Amendment stating "none of the funds available for injury prevention and control at the Centers for Disease Control and Prevention may be used to advocate or promote gun control" as a rider in the 1996 appropriations bill.[23][24] Advocates for gun control opposed the amendment and continued to try to overturn it after it was passed.[25] In 1997, "Congress re-directed all of the money for gun research to the study of traumatic brain injury."[23] David Satcher, CDC head 1993–98[26] advocated for firearms research.[23]

On April 21, 2005, then–CDC director Julie Gerberding formally announced the reorganization of CDC to "confront the challenges of 21st-century health threats".[27] She established four coordinating centers. In 2009 the Obama administration re-evaluated this change and ordered them cut as an unnecessary management layer.[28]

On May 16, 2011, the Centers for Disease Control and Prevention's blog published an article instructing the public on what to do to prepare for a zombie invasion. While the article did not claim that such a scenario was possible, it did use the popular culture appeal as a means of urging citizens to prepare for all potential hazards, such as earthquakes, tornadoes, and floods.[29]

According to David Daigle, the associate director for communications, public health preparedness and response, the idea arose when his team was discussing their upcoming hurricane-information campaign and Daigle mused that "we say pretty much the same things every year, in the same way, and I just wonder how many people are paying attention." A social-media employee mentioned that the subject of zombies had come up a lot on Twitter when she had been tweeting about the Fukushima Daiichi nuclear disaster and radiation. The team realized that a campaign like this would most likely reach a different audience from the one that normally pays attention to hurricane-preparedness warnings and went to work on the zombie campaign, launching it right before hurricane season began. "The whole idea was, if you're prepared for a zombie apocalypse, you're prepared for pretty much anything," said Daigle.[30]

Once the blog article was posted, the CDC announced an open contest for YouTube submissions of the most creative and effective videos covering preparedness for a zombie apocalypse (or apocalypse of any kind), to be judged by the "CDC Zombie Task Force". Submissions were open until October 11, 2011.[31] They also released a zombie-themed graphic novella available on their website.[32] Zombie-themed educational materials for teachers are available on the site.[33]

In 2013, the American Medical Association, the American Psychological Association, and the American Academy of Pediatrics sent a letter to the leaders of the Senate Appropriations Committee asking them "to support at least $10 million within the Centers for Disease Control and Prevention (CDC) in FY 2014 along with sufficient new taxes at the National Institutes of Health to support research into the causes and prevention of violence. Furthermore, we urge Members to oppose any efforts to reduce, eliminate, or condition CDC funding related to violence prevention research."[34] Congress maintained the ban in subsequent budgets.[25] In 2016 over a dozen "public health insiders, including current and former CDC senior leaders" told The Trace interviewers that CDC senior leaders took a cautious stance in their interpretation of the Dickey Amendment and that they could do more but were afraid of political and personal retribution.[23]

As of 2013, the CDC's Biosafety Level 4 laboratories were among the few that exist in the world.[35] They included one of only two official repositories of smallpox in the world, with the other one located at the State Research Center of Virology and Biotechnology VECTOR in the Russian Federation. In 2014, the CDC revealed they had discovered several misplaced smallpox samples while their lab workers were "potentially infected" with anthrax.[36]

The city of Atlanta annexed the property of the CDC headquarters effective January 1, 2018, as a part of the city's largest annexation within a period of 65 years; the Atlanta City Council had voted to do so the prior December.[3] The CDC and Emory University had requested that the Atlanta city government annex the area, paving the way for a MARTA expansion through the Emory campus, funded by city tax dollars.[37] The headquarters were located in an unincorporated area,[38] statistically in the Druid Hills census-designated place.[39]

COVID-19

[edit]

The CDC has been widely criticized for its handling of the COVID-19 pandemic. In 2022, CDC director Rochelle Walensky acknowledged "some pretty dramatic, pretty public mistakes, from testing to data to communications", based on the findings of an internal examination.[40]

The first confirmed case of COVID-19 was discovered in the U.S. on January 20, 2020.[41] However, widespread COVID-19 testing in the United States was effectively stalled until February 28, when federal officials revised a faulty CDC test, and days afterward, when the Food and Drug Administration began loosening rules that had restricted other labs from developing tests.[42] In February 2020, as the CDC's early coronavirus test malfunctioned nationwide,[43] CDC Director Robert R. Redfield reassured fellow officials on the White House Coronavirus Task Force that the problem would be quickly solved, according to White House officials. It took about three weeks to sort out the failed test kits, which may have been contaminated during their processing in a CDC lab. Later investigations by the FDA and the Department of Health and Human Services found that the CDC had violated its own protocols in developing its tests.[43][44] In November 2020, NPR reported that an internal review document they obtained revealed that the CDC was aware that the first batch of tests which were issued in early January had a chance of being wrong 33 percent of the time, but they released them anyway.[45]

In May 2020, The Atlantic reported that the CDC was conflating the results of two different types of coronavirus tests – tests that diagnose current coronavirus infections, and tests that measure whether someone has ever had the virus. The magazine said this distorted several important metrics, provided the country with an inaccurate picture of the state of the pandemic, and overstated the country's testing ability.[46]

In July 2020, the Trump administration ordered hospitals to bypass the CDC and instead send all COVID-19 patient information to a database at the Department of Health and Human Services. Some health experts opposed the order and warned that the data might become politicized or withheld from the public.[47] On July 15, the CDC alarmed health care groups by temporarily removing COVID-19 dashboards from its website. It restored the data a day later.[48][49][50]

In August 2020, the CDC recommended that people showing no COVID-19 symptoms do not need testing. The new guidelines alarmed many public health experts.[51] The guidelines were crafted by the White House Coronavirus Task Force without the sign-off of Anthony Fauci of the NIH.[52][53] Objections by other experts at the CDC went unheard. Officials said that a CDC document in July arguing for "the importance of reopening schools" was also crafted outside the CDC.[54] On August 16, the chief of staff, Kyle McGowan, and his deputy, Amanda Campbell, resigned from the agency.[55] The testing guidelines were reversed on September 18, 2020, after public controversy.[56]

In September 2020, the CDC drafted an order requiring masks on all public transportation in the United States, but the White House Coronavirus Task Force blocked the order, refusing to discuss it, according to two federal health officials.[57]

In October 2020, it was disclosed that White House advisers had repeatedly altered the writings of CDC scientists about COVID-19, including recommendations on church choirs, social distancing in bars and restaurants, and summaries of public-health reports.[58]

In the lead up to 2020 Thanksgiving, the CDC advised Americans not to travel for the holiday saying, "It's not a requirement. It's a recommendation for the American public to consider." The White House coronavirus task force had its first public briefing in months on that date but travel was not mentioned.[59]

The New York Times later concluded that the CDC's decisions to "ben[d] to political pressure from the Trump White House to alter key public health guidance or withhold it from the public [...] cost it a measure of public trust that experts say it still has not recaptured" as of 2022.[40]

In May 2021, following criticism by scientists, the CDC updated its COVID-19 guidance to acknowledge airborne transmission of COVID-19, after having previously claimed that the majority of infections occurred via "close contact, not airborne transmission".[60]

In December 2021, following a request from the CEO of Delta Air Lines, CDC shortened its recommended isolation period for asymptomatic individuals infected with COVID-19 from 10 days to five.[61][62][63]

Until 2022, the CDC withheld critical data about COVID-19 vaccine boosters, hospitalizations and wastewater data.[64]

On June 10, 2022, the Biden Administration ordered the CDC to remove the COVID-19 testing requirement for air travelers entering the United States.[65]

Morbidity and Mortality Weekly Report modifications

[edit]

During the pandemic, the CDC Morbidity and Mortality Weekly Report (MMWR) came under pressure from political appointees at the Department of Health and Human Services (HHS) to modify its reporting so as not to conflict with what Trump was saying about the pandemic.[66]

Starting in June 2020, Michael Caputo, the HHS assistant secretary for public affairs, and his chief advisor Paul Alexander tried to delay, suppress, change, and retroactively edit MMR releases about the effectiveness of potential treatments for COVID-19, the transmissibility of the virus, and other issues where the president had taken a public stance.[66] Alexander tried unsuccessfully to get personal approval of all issues of MMWR before they went out.[67]

Caputo claimed this oversight was necessary because MMWR reports were being tainted by "political content"; he demanded to know the political leanings of the scientists who reported that hydroxychloroquine had little benefit as a treatment while Trump was saying the opposite.[66] In emails Alexander accused CDC scientists of attempting to "hurt the president" and writing "hit pieces on the administration".[68]

In October 2020, emails obtained by Politico showed that Alexander requested multiple alterations in a report. The published alterations included a title being changed from "Children, Adolescents, and Young Adults" to "Persons." One current and two former CDC officials who reviewed the email exchanges said they were troubled by the "intervention to alter scientific reports viewed as untouchable prior to the Trump administration" that "appeared to minimize the risks of the coronavirus to children by making the report's focus on children less clear."[69]

Trust in the CDC after COVID-19

[edit]

A poll conducted in September 2020 found that nearly 8 in 10 Americans trusted the CDC, a decrease from 87 percent in April 2020. Another poll showed an even larger drop in trust with the results dropping 16 percentage points.[70] By January 2022, according to an NBC News poll, only 44% of Americans trusted the CDC compared to 69% at the beginning of the pandemic.[71] As the trustworthiness eroded, so too did the information it disseminates.[55] The diminishing level of trust in the CDC and the information releases also incited "vaccine hesitancy" with the result that "just 53 percent of Americans said they would be somewhat or extremely likely to get a vaccine."[70]

In September 2020, amid the accusations and the faltering image of the CDC, the agency's leadership was called into question. Former acting director at the CDC, Richard Besser, said of Redfield that "I find it concerning that the CDC director has not been outspoken when there have been instances of clear political interference in the interpretation of science."[72] In addition, Mark Rosenberg, the first director of CDC's National Center for Injury Prevention and Control, also questioned Redfield's leadership and his lack of defense of the science.[72]

Historically, the CDC has not been a political agency; however, the COVID-19 pandemic, and specifically the Trump administration's handling of the pandemic, resulted in a "dangerous shift" according to a previous CDC director and others. Four previous directors claim that the agency's voice was "muted for political reasons."[73] Politicization of the agency has continued into the Biden administration as COVID-19 guidance is contradicted by State guidance[74] and the agency is criticized as "CDC's credibility is eroding".[75]

In 2021, the CDC, then under the leadership of the Biden administration, received criticism for its mixed messaging surrounding COVID-19 vaccines, mask-wearing guidance, and the state of the pandemic.[76][77]

On August 17, 2022, Walensky said the CDC would make drastic changes in the wake of mistakes during the COVID-19 pandemic. She outlined an overhaul of how the CDC would analyze and share data and how they would communicate information to the general public. In her statement to all CDC employees, she said: "For 75 years, CDC and public health have been preparing for COVID-19, and in our big moment, our performance did not reliably meet expectations."[78] Based on the findings of an internal report, Walensky concluded that "The CDC must refocus itself on public health needs, respond much faster to emergencies and outbreaks of disease, and provide information in a way that ordinary people and state and local health authorities can understand and put to use" (as summarized by the New York Times).[40]

Second Trump administration

[edit]

In January 2025, it was reported that a CDC official had ordered all CDC staff to stop working with the World Health Organization.[79] Around January 31, 2025, several CDC websites, pages, and datasets related to HIV and STI prevention, LGBT and youth health became unavailable for viewing after the agency was ordered to comply with Donald Trump's executive order to remove all material of "diversity, equity, and inclusion" and "gender identity".[80][81] Also in January 2025, due to a pause in communications imposed by the second Trump administration at federal health agencies, publication of the Morbidity and Mortality Weekly Report (MMWR) was halted, the first time that had happened since its inception in 1960. The president of the Infectious Diseases Society of America (IDSA) called the pause in publication a "disaster." Attempts to halt publication had been made by the first Trump administration after MMWR published information about COVID-19 that "conflicted with messaging from the White House." The pause in communications also caused the cancellation of a meeting between the CDC and IDSA about threats to public health regarding the H5N1 influenza virus.[82]

On February 1, 2025, the CDC ordered its scientists to retract any not yet published research they had produced which included any of the following banned terms: "Gender, transgender, pregnant person, pregnant people, LGBT, transsexual, non-binary, nonbinary, assigned male at birth, assigned female at birth, biologically male, biologically female".[83] Larry Gostin, director of the World Health Organization Center on Global Health Law, said that the directive amounted to censorship of not only government employees, but private citizens as well. For example, if the lead author of a submitted paper works for the CDC and withdraws their name from the submission, that kills the submission even if coauthors who are private scientists remain on it.[84] Other censored topics include DEI, climate change, and HIV.[85][86]

Following extensive public backlash, some, but not all, of the removed pages were reinstated.[87] The CDC's censorship led to many researchers and journalists to preserve databases themselves, with many removed articles being uploaded to archival sites such as the Internet Archive.[88]

On February 4, Doctors for America filed a federal lawsuit against the CDC, Food and Drug Administration, and Department of Health and Human Services, asking the removed websites to be put back online.[89] On February 11, a judge ordered removed pages to be restored temporarily while the suit is being considered, citing doctors who said the removed materials were "vital for real-time clinical decision-making".[90][91]

On February 14, 2025, around 1,300 CDC employees were laid off by the administration, which included all first-year officers of the Epidemic Intelligence Service.[92] The cuts also terminated 16 of the 24 Laboratory Leadership Service program fellows, a program designed for early-career lab scientists to address laboratory testing shortcomings of the CDC.[93] In the following month, the Trump administration quietly withdrew its CDC director nominee, Dave Weldon, just minutes before his scheduled Senate confirmation hearing on March 13.[94]

In April 2025, it was reported that among the reductions is the elimination of the Freedom of Information Act team, the Division of Violence Prevention, laboratories involved in testing for antibiotic resistance, and the team responsible for determining recalls of hazardous infant products.[95] Additional cuts affect the technology branch of the Center for Forecasting and Outbreak Analytics, which includes software engineers and computer scientists supporting the centre established during the COVID-19 pandemic to improve disease outbreak prediction.[95]

In August 2025, over 600 CDC employees were laid off and a number of programs completely dismantled, including "[m]aternal and child health services, oral health programs, and the CDC's long-running Violence Against Children and Youth Surveys (VACS)."[96] Experts have criticized the mass layoffs under Secretary of Health and Human Services Robert F. Kennedy Jr. for creating dangerous gaps in public health.[97] VACS, for instance, has played an essential role in gathering high-quality, actionable data used to assess and mitigate violent harm against children, with such harm being estimated as affecting half of all children worldwide.[98][99]

2025 headquarters shooting

[edit]

On August 8, 2025, 30-year-old Patrick Joseph White of Kennesaw, Georgia, attacked the CDC's Roybal Campus in Atlanta, Georgia. White attempted to enter the headquarters, but was thwarted by security. White then drove across the street to a CVS Pharmacy where he barricaded himself inside on the second floor, and fired at the campus with a rifle, striking four CDC buildings on multiple floors over 180 times, breaking about 150 windows and piercing some of the blast-resistant windows; authorities recovered more than 500 shell casings and five firearms after the shooting.[100][101] 33-year-old David Rose, a DeKalb County Police Department officer, was fatally wounded by White as he arrived on the scene.[102] Officers entered the pharmacy and found White dead from a self-inflicted gunshot wound.[103][104]

White is believed to have been motivated by distrust in vaccines, and believed the COVID-19 vaccine had made him depressed and suicidal.[102] He had reached out for mental health assistance for weeks before the attack.[102] Fired But Fighting, a group of laid-off CDC employees, blamed the attack on the anti-vaccine rhetoric of members of the Trump administration, saying that Secretary of Health and Human Services, Robert F. Kennedy Jr., "is directly responsible for the villainization of CDC's workforce through his continuous lies about science and vaccine safety".[105][102] A union representing CDC employees called on both the CDC and the leadership of the Department of Health and Human Services to denounce vaccine misinformation, and said that the attack was a result of compounding misinformation and obloquy towards science and health officials. While Kennedy Jr. had reached out to CDC staff and said "no one should face violence while working to protect the health of others", Dr. Jerome Adams, a former Surgeon General, described Kennedy Jr.'s response as "tepid" and that Kennedy Jr. must do more given his past "inflammatory rhetoric".[106] On August 11, Kennedy Jr. toured the Roybal Campus with deputy secretary Jim O'Neill and CDC director Susan Monarez, but did not speak with the media during the visit, although he did meet privately with Rose's widow.[100] A day later, in an interview with Scripps News, when Kennedy Jr. was asked if he had a message for CDC employees concerned about the consequences of misinformation about vaccines, he said political violence was "wrong" and claimed not enough was known about White's motives yet to draw conclusions before criticizing the government's previous vaccination efforts as "overreaching" and that the government had said "things that are not always true" in order to get people vaccinated.[107] Trump did not respond to the shooting of the police officer.[108][109]

White's father spoke in an interview with WANF, saying that he and his wife were watching a cable television network in their Kennesaw home when the phone rang. He picked up the phone and attempted to have a normal conversation with his son. White spoke to his father, "I'm gonna shoot up the CDC", before hanging up afterward. The couple immediately changed their channel to one of the Atlanta stations, where his father saw the unmistakable image of his car at the scene.[110]

2025 advisory committee purge and leadership dispute

[edit]

On May 14, 2025, HHS Secretary Robert F. Kennedy Jr. stated that lawyer Matthew Buzzelli was acting CDC director, though it was not listed on the CDC website.[111][112]

In June 2025, RFK, Jr. fired all 17 members of the Advisory Committee on Immunization Practices (ACIP) and—with one exception—appointed members who are either anti-vaccine activists or who lack expertise in vaccines.[113]

Susan Monarez was confirmed as CDC head on July 31, 2025, but on August 27, it was announced on X (formerly Twitter) that she had been fired. Monarez disputed the legality of the firing, as it had not been carried out by the President, and it had been falsely reported that she had resigned. The President later officially carried out the firing.[114][115] Monarez was fired after refusing to rubber stamp what were expected to be unscientific recommendations from ACIP and to fire senior staff vaccine experts.[116] The next day, the Trump administration announced the selection of Deputy Secretary of Health and Human Services Jim O'Neill as a replacement.[117]

Following news of Monarez's ouster, at least four other CDC senior officials announced their resignations:[118][119][120]

Dozens of CDC employees walked out of headquarters and protested in support of Monarez and the departing officials.[121]

Organization

[edit]
CDC's Roybal campus in Atlanta, Georgia
Tom Harkin Global Communications Center
CDC Building 17 in Atlanta, Georgia, as seen from Emory University

The CDC is organized into centers, institutes, and offices (CIOs), with each organizational unit implementing the agency's activities in a particular area of expertise while also providing intra-agency support and resource-sharing for cross-cutting issues and specific health threats.[7]

As of the most recent reorganization in February 2023, the CIOs are:[122]

The Office of Public Health Preparedness was created during the 2001 anthrax attacks shortly after the terrorist attacks of September 11, 2001. Its purpose was to coordinate among the government the response to a range of biological terrorism threats.[124]

Locations

[edit]

Most CDC centers are located in the Atlanta metropolitan area, where it has three major campuses:

  • The Chamblee Campus in Chamblee, Georgia, opened in 1946, inheriting the site and buildings of Lawson General Hospital immediately adjacent to but not part of Naval Air Station Atlanta. Although it was initially planned to be shut down when the Roybal Campus opened, it was found that the latter was not suitable for live animal facilities. The buildings were slowly replaced with modern buildings over time.[125][126]
  • The Roybal Campus in Atlanta is the largest, named in honor of the late representative Edward R. Roybal. It was originally called the Clifton Road Campus. Although its land was donated by adjacent Emory University in 1947, it did not open until 1960.[127] Its Building 18, which opened in 2005, contains the premier BSL4 laboratory in the United States.[128][129][130]
  • The Lawrenceville Campus in Lawrenceville, Georgia, was acquired with the intent of being a destination for Chamblee's animal facilities if that campus was shut down.[125] It was first developed in the early 1960s.[131]

A few of the centers are based in or operate other domestic locations:[132]

Budget

[edit]

The CDC budget for fiscal year 2024 is $11.581 billion.[134]

Workforce

[edit]

As of 2021, CDC staff numbered approximately 15,000 personnel (including 6,000 contractors and 840 United States Public Health Service Commissioned Corps officers) in 170 occupations. Eighty percent held bachelor's degrees or higher; almost half had advanced degrees (a master's degree or a doctorate such as a PhD, D.O., or M.D.).[135]

Common CDC job titles include engineer, entomologist, epidemiologist, biologist, physician, veterinarian, behavioral scientist, nurse, medical technologist, economist, public health advisor, health communicator, toxicologist, chemist, computer scientist, and statistician.[136] The CDC also operates a number of notable training and fellowship programs, including those indicated below.

Epidemic Intelligence Service (EIS)

[edit]

The Epidemic Intelligence Service (EIS) is composed of "boots-on-the-ground disease detectives" who investigate public health problems domestically and globally.[137] When called upon by a governmental body, EIS officers may embark on short-term epidemiological assistance assignments, or "Epi-Aids", to provide technical expertise in containing and investigating disease outbreaks.[138][139][140] The EIS program is a model for the international Field Epidemiology Training Program.

Public Health Associates Program

[edit]

The CDC also operates the Public Health Associate Program (PHAP), a two-year paid fellowship for recent college graduates to work in public health agencies all over the United States. PHAP was founded in 2007 and currently[when?] has 159 associates in 34 states.[141]

Leadership

[edit]
David Sencer points to a depiction of Triatomine sp., which transmits Chagas disease.

The director of the CDC is a position that currently requires Senate confirmation. The director serves at the pleasure of the President and may be fired at any time. The CDC director concurrently serves as the Administrator of the Agency for Toxic Substances and Disease Registry.[142]

Prior to January 20, 2025, it was a Senior Executive Service position[143] that could be filled either by a career employee, or as a political appointment that does not require Senate confirmation, with the latter method typically being used.[20][144][145] The change to requiring Senate confirmation was due to a provision in the Consolidated Appropriations Act, 2023.[146]

Twenty directors have[when?] served the CDC or its predecessor agencies, including three who have served during the Trump administration (including Anne Schuchat who twice served as acting director)[8][147] and three who have served during the Carter administration (including one acting director not shown here).[148] Two served under Bill Clinton, but only one under the Nixon to Ford terms.

List of directors

[edit]

The following persons have served as the director of the Centers for Disease Control and Prevention (or chief of the Communicable Disease Center):[149]


No. Portrait Director Term start Term end Refs.
1 Louis L. Williams Jr. 1942 1943
2 Mark D. Hollis 1944 1946
3 Raymond A. Vonderlehr 1947 December 1951 [150]
4 Justin M. Andrews January 1952 January 1953 [151]
5 Theodore J. Bauer January 15, 1953 August 1956 [152][153]
6 Robert J. Anderson October 1, 1956 June 30, 1960 [154][155]
7 Clarence A. Smith July 1960 August 1962 [156][157]
8 James L. Goddard September 1, 1962 January 1966 [158]
9 David J. Sencer February 1966 May 1977 [159][160][161]
10 William H. Foege May 1977 November 30, 1983 [162][163]
11 James O. Mason December 1, 1983 April 1989 [164][165]
Acting Walter Dowdle April 1989 February 28, 1990
12 William L. Roper March 1, 1990 June 30, 1993 [166][167]
Acting Walter Dowdle July 1, 1993 November 14, 1993 [168]
13 David Satcher November 15, 1993 February 13, 1998 [169][170][171]
Acting Claire V. Broome February 14, 1998 October 4, 1998
14 Jeffrey P. Koplan October 5, 1998 March 31, 2002 [172][173][174]
acting David Fleming April 1, 2002 June 2, 2002 [175]
15 Julie Gerberding June 3, 2002 January 20, 2009 [176][177]
interim William Gimson January 20, 2009 January 22, 2009 [178]
acting Richard Besser January 22, 2009 June 7, 2009 [179]
16 Thomas R. Frieden June 8, 2009 January 20, 2017 [144][180]
acting Anne Schuchat January 20, 2017 July 6, 2017 [181]
17 Brenda Fitzgerald July 7, 2017 January 31, 2018 [182]
acting Anne Schuchat February 1, 2018 March 26, 2018 [183]
18 Robert R. Redfield March 26, 2018 January 20, 2021 [184][185]
19 Rochelle Walensky January 20, 2021 June 30, 2023 [186][187]
acting Nirav D. Shah July 1, 2023 July 10, 2023 [188]
20 Mandy Cohen July 10, 2023 January 20, 2025 [189]
acting Susan Monarez January 23, 2025 March 24, 2025 [190][191]
acting Matthew Buzzelli March 24, 2025 July 30, 2025 [112]
21 Susan Monarez July 31, 2025 August 27, 2025[a] [192][193]
acting Jim O'Neill August 28, 2025 Incumbent [194]
  1. ^ Monarez was dismissed from her role, but has disputed the legality of her dismissal and refused to leave her post.[195]

Datasets and survey systems

[edit]

Areas of focus

[edit]
Donald Henderson as part of the CDC's smallpox eradication team in 1966

Communicable diseases

[edit]

The CDC's programs address more than 400 diseases, health threats, and conditions that are major causes of death, disease, and disability. The CDC's website has information on various infectious (and noninfectious) diseases, including smallpox, measles, and others.

Influenza

[edit]

The CDC targets the transmission of influenza, including the H1N1 swine flu, and launched websites to educate people about hygiene.[204]

Division of Select Agents and Toxins

[edit]
CDC and MSF staff preparing to enter an Ebola treatment unit in Liberia, August 2014

Within the division are two programs: the Federal Select Agent Program (FSAP) and the Import Permit Program. The FSAP is run jointly with an office within the U.S. Department of Agriculture, regulating agents that can cause disease in humans, animals, and plants. The Import Permit Program regulates the importation of "infectious biological materials."[205]

The CDC runs a program that protects the public from rare and dangerous substances such as anthrax and the Ebola virus. The program, called the Federal Select Agent Program, calls for inspections of labs in the U.S. that work with dangerous pathogens.[206]

During the 2014 Ebola outbreak in West Africa, the CDC helped coordinate the return of two infected American aid workers for treatment at Emory University Hospital, the home of a special unit to handle highly infectious diseases.[207]

As a response to the 2014 Ebola outbreak, Congress passed a Continuing Appropriations Resolution allocating $30,000,000 towards CDC's efforts to fight the virus.[208]

Non-communicable diseases

[edit]

The CDC also works on non-communicable diseases, including chronic diseases caused by obesity, physical inactivity and tobacco-use.[209] The work of the Division for Cancer Prevention and Control, led from 2010 by Lisa C. Richardson, is also within this remit.[210][211]

Antibiotic resistance

[edit]

The CDC implemented their National Action Plan for Combating Antibiotic Resistant Bacteria as a measure against the spread of antibiotic resistance in the United States. This initiative has a budget of $161 million and includes the development of the Antibiotic Resistance Lab Network.[212]

Global health

[edit]

Globally, the CDC works with other organizations to address global health challenges and contain disease threats at their source. They work with many international organizations such as the World Health Organization (WHO) as well as ministries of health and other groups on the front lines of outbreaks. The agency maintains staff in more than 60 countries, including some from the U.S. but more from the countries in which they operate.[213] The agency's global divisions include the Division of Global HIV and TB (DGHT), the Division of Parasitic Diseases and Malaria (DPDM), the Division of Global Health Protection (DGHP), and the Global Immunization Division (GID).[214]

The CDC has been working with the WHO to implement the International Health Regulations (IHR), an agreement between 196 countries to prevent, control, and report on the international spread of disease, through initiatives including the Global Disease Detection Program (GDD).[215]

The CDC has also been involved in implementing the U.S. global health initiatives President's Emergency Plan for AIDS Relief (PEPFAR) and President's Malaria Initiative.[216]

Travelers' health

[edit]

The CDC collects and publishes health information for travelers in a comprehensive book, CDC Health Information for International Travel, which is commonly known as the "yellow book."[217] The book is available online and in print as a new edition every other year and includes current travel health guidelines, vaccine recommendations, and information on specific travel destinations. The CDC also issues travel health notices on its website, consisting of three levels:

  • "Watch": Level 1 (practice usual precautions)
  • "Alert": Level 2 (practice enhanced precautions)
  • "Warning": Level 3 (avoid nonessential travel)[218]

Vaccine safety

[edit]

The CDC uses a number of tools to monitor the safety of vaccines. The Vaccine Adverse Event Reporting System (VAERS), a national vaccine safety surveillance program run by CDC and the FDA. "VAERS detects possible safety issues with U.S. vaccines by collecting information about adverse events (possible side effects or health problems) after vaccination."[219] The CDC's Safety Information by Vaccine page provides a list of the latest safety information, side effects, and answers to common questions about CDC recommended vaccines.[220]

The Vaccine Safety Datalink (VSD) works with a network of healthcare organizations to share data on vaccine safety and adverse events.[221] The Clinical Immunization Safety Assessment (CISA) project is a network of vaccine experts and health centers that research and assist the CDC in the area of vaccine safety.[222]

CDC also runs a program called V-safe, a smartphone web application that allows COVID-19 vaccine recipients to be surveyed in detail about their health in response to getting the shot.[223]

CDC Foundation

[edit]

The CDC Foundation operates independently from CDC as a private, nonprofit 501(c)(3) organization incorporated in the State of Georgia. The creation of the Foundation was authorized by section 399F of the Public Health Service Act to support the mission of CDC in partnership with the private sector, including organizations, foundations, businesses, educational groups, and individuals.[224][225] From 1995 to 2022, the foundation raised over $1.6 billion and launched more than 1,200 health programs.[226] Bill Cosby formerly served as a member of the foundation's Board of Directors, continuing as an honorary member after completing his term.[227]

The foundation engages in research projects and health programs in more than 160 countries every year, including in focus areas such as cardiovascular disease, cancer, emergency response, and infectious diseases, particularly HIV/AIDS, Ebola, rotavirus, and COVID-19.[226]

  • EmPOWERED Health Program: Launched in November 2019 with funding from Amgen, the program works to empower cancer patients to become actively involved in the decision making around their treatments.[228][229]
  • Fries Prize for Improving Health: An annual prize first awarded in 1992 that "recognizes an individual who has made major accomplishments in health improvement and with the general criteria of the greatest good for the greatest number".[230]

In 2015, BMJ associate editor Jeanne Lenzer raised concerns that the CDC's recommendations and publications may be influenced by donations received through the Foundation, which includes pharmaceutical companies.[231]

Publications

[edit]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
The Centers for Disease Control and Prevention (CDC) is a United States federal public health agency within the Department of Health and Human Services, tasked with protecting public health and safety by preventing and controlling disease, injury, and disability both domestically and internationally through scientific research, surveillance, and guidance. Founded on July 1, 1946, as the Communicable Disease Center in Atlanta, Georgia, with an initial focus on malaria eradication following World War II, the agency has since broadened its scope to encompass epidemiology, vaccination programs, outbreak response, and chronic disease prevention, operating from its headquarters at 1600 Clifton Road. Its name evolved to Centers for Disease Control in 1970 and added "Prevention" in 1992 to reflect expanded responsibilities in health promotion and risk reduction. The CDC has achieved notable successes in infectious disease control, including contributions to the global eradication of smallpox through collaboration with the World Health Organization, the elimination of polio and measles from endemic transmission in the United States via vaccination campaigns, and advancements in managing HIV/AIDS and tuberculosis epidemics through surveillance and treatment guidelines. Domestically, it has supported reductions in vaccine-preventable diseases, improved food and water safety standards, and developed tools like Epi Info for outbreak investigations used worldwide. These efforts have been grounded in empirical data collection and epidemiological methods, enabling targeted interventions that have averted millions of illnesses and deaths. However, the agency has faced significant controversies, particularly regarding its response to the COVID-19 pandemic, where empirical analyses have highlighted shortcomings such as delayed diagnostic testing rollout, inconsistent masking and social distancing recommendations amid evolving evidence, and overreliance on modeled projections that diverged from real-time causal data on transmission dynamics. Surveys indicate a substantial decline in public trust, with statistically significant drops in confidence attributed to perceived politicization, equivocal messaging, and institutional failures in adapting to empirical shifts in viral behavior and immunity. Critics, drawing from peer-reviewed reviews, argue these issues stem from structural disinvestment in core surveillance capacities and leadership decisions prioritizing narrative consistency over transparent data-driven revisions, exacerbating excess mortality and long-term skepticism toward public health mandates. Such challenges underscore ongoing debates about balancing precautionary principles with causal evidence in policy formulation.

History

Establishment and Initial Focus (1946–1950s)

The Communicable Disease Center (CDC) was established on July 1, 1946, by the U.S. Public Health Service as a field unit under the Bureau of State Services, succeeding the wartime Malaria Control in War Areas (MCWA) program initiated in 1942 to prevent malaria outbreaks near southern military bases and war production sites. Headquartered in Atlanta, Georgia—a location chosen due to the MCWA's existing operations and the prevalence of malaria in the southeastern United States—the agency began operations in a single-floor office within a former military facility on the Clifton Road campus. Dr. Joseph W. Mountin, chief of the Bureau of State Services and a key advocate for broadening public health efforts, played a pivotal role in its founding, envisioning it as a hub for practical disease control beyond immediate wartime needs. The CDC's initial mandate centered on the investigation and control of communicable diseases, with malaria as the overriding priority; its staff, numbering 369 employees including entomologists, engineers, and just seven medical officers, emphasized vector control through mosquito abatement techniques such as draining breeding sites, applying insecticides, and spraying over six million homes in collaboration with state and local health departments. Operating on an initial budget of approximately $1 million, the agency provided training to thousands of state sanitarians in epidemiology and laboratory methods while conducting field surveillance for typhus and other insect-borne pathogens. By 1947, the National Malaria Eradication Program formalized these efforts, achieving a drastic reduction in U.S. cases from over 400,000 annually in the early 1940s to fewer than 2,000 by 1950, culminating in malaria's effective elimination from the country by 1951. During the late and , the CDC gradually broadened its scope under Mountin's influence to encompass other communicable threats, including intelligence services for tracking outbreaks and laboratory support for diagnostic testing, while maintaining a focus on practical assistance to state health agencies rather than direct regulation. This era solidified the agency's role in applied , with activities such as training and early epidemiological fieldwork laying groundwork for future expansions, though its resources remained modest compared to later growth.

Expansion into Broader Public Health (1960s–1970s)

During the 1960s, the Communicable Disease Center underwent significant restructuring to address emerging public health challenges beyond infectious diseases. In 1967, it was redesignated as the National Communicable Disease Center, reflecting an emphasis on national coordination of disease surveillance and control efforts. By 1970, the agency's name was changed to the Center for Disease Control (singular), signaling a deliberate expansion into non-communicable areas such as chronic disease prevention, environmental hazards, injury control, and occupational safety, as its activities had outgrown the communicable disease focus. This shift was driven by accumulating evidence on chronic disease etiology and the need for federal intervention in multifaceted health threats. Under Director David J. Sencer, who served from 1966 to 1977, the CDC strengthened its role in immunization programs, including the promotion of the Sabin oral polio vaccine following its 1961 licensure, and expanded epidemiological expertise to state and local health departments. The agency initiated investigations into environmental health issues, such as leukemia clusters and birth defects, laying the groundwork for the later Center for Environmental Health. In response to growing concerns over workplace hazards, the Occupational Safety and Health Act of 1970 established the National Institute for Occupational Safety and Health (NIOSH) within the CDC, tasked with research, training, and recommendations to prevent occupational illnesses and injuries. These developments marked the CDC's transition toward a comprehensive public health institution, incorporating surveillance and intervention for chronic conditions like cardiovascular disease and cancer, where 1960s-1970s research increasingly emphasized modifiable risk factors and behavioral interventions. By the mid-1970s, the CDC had integrated programs in and , further broadening its scope to address determinants of . This era's expansions were supported by congressional mandates and collaborations with other federal entities, enhancing the agency's capacity for data-driven policy influence despite limited resources compared to later decades.

Reorganization and Specialization (1980s–2018)

In 1980, the Communicable Disease Center was renamed the Centers for Disease Control, reflecting the agency's expansion into multiple specialized organizational units focused on diverse public health threats. This change, effective October 14, 1980, aligned with a broader shift toward decentralized structures comprising distinct centers for infectious diseases, environmental health, and occupational safety. An extensive internal reorganization followed in 1981, formalizing the plural "Centers" designation and enhancing coordination for emerging epidemics. The HIV/AIDS epidemic, first documented by CDC in June 1981 through reports of unusual Pneumocystis pneumonia cases among gay men in Los Angeles, drove significant specialization in infectious disease control. By 1983, CDC had established dedicated surveillance systems and the Division of HIV/AIDS within the Center for Infectious Diseases, allocating resources for contact tracing, behavioral interventions, and laboratory diagnostics amid over 3,000 reported U.S. cases by year's end. This response expanded CDC's epidemiological workforce, with field investigations identifying risk factors like blood transfusions and heterosexual transmission by 1985, leading to the creation of specialized branches for viral hepatitis and sexually transmitted infections. By the late 1980s, these efforts had evolved into the AIDS Prevention Program, emphasizing prevention strategies that reduced new infections through targeted education and screening, though initial underfunding delayed full implementation until congressional appropriations increased in 1988. During the 1990s, under directors James Mason (1983–1990) and William Roper (1990–1993), CDC formalized four core centers established in the prior decade: the Center for Infectious Diseases, Center for Chronic Disease Prevention and Health Promotion, Center for Environmental Health and Injury Control, and the quasi-independent National Institute for Occupational Safety and Health. In 1992, the Public Health Service Act was amended to expand CDC's mandate beyond control to explicit prevention activities, prompting a 1993 name change to Centers for Disease Control and Prevention. This period saw specialization in chronic conditions, with the creation of divisions for diabetes, cancer, and injury prevention, supported by data showing noncommunicable diseases accounting for over 60% of U.S. preventable deaths by 1990. The Agency for Toxic Substances and Disease Registry (ATSDR), established under the 1980 Comprehensive Environmental Response, Compensation, and Liability Act and operationalized in 1985, operated under CDC's administrative umbrella, integrating environmental toxicology expertise for Superfund site assessments. Post-9/11 bioterrorism concerns, including the 2001 anthrax attacks that killed five and infected 17, accelerated reorganization under Director Jeffrey Koplan (1998–2002) and successor Julie Gerberding (2002–2009). In 2003, Gerberding launched the Futures Initiative, a sweeping restructuring that consolidated over 100 programs into eight coordinating centers—such as the Coordinating Center for Infectious Diseases and Coordinating Center for Health Promotion—to foster cross-disciplinary integration and rapid emergency response. This matrix-style model aimed to address siloed operations revealed by anthrax investigations, enabling unified command during crises like the 2003 SARS outbreak, where CDC deployed over 50 staff to coordinate global containment. However, the reform drew criticism from unions and employees for flattening hierarchies, increasing administrative burdens, and contributing to a reported "brain drain" of senior scientists, with surveys indicating up to 20% staff dissatisfaction by 2006. A 2004 Government Accountability Office review credited the structure with improving crisis management but noted ongoing leadership strains on Gerberding's time. Under Tom Frieden (2009–2017), CDC emphasized evidence-based interventions for chronic diseases, expanding the Center for Chronic Disease Prevention and Health Promotion with programs targeting tobacco use (reducing adult smoking prevalence from 20.9% in 2005 to 15.5% in 2016) and obesity. The 2014 Ebola outbreak, involving 28 U.S. cases and one death, tested these structures, prompting temporary activations of the Emergency Operations Center and refinements to global health security divisions, though internal reviews highlighted communication gaps. By 2018, under interim leadership following Frieden's tenure, CDC maintained 10 major centers and offices, with specialization extending to zoonotic diseases and antimicrobial resistance via the National Center for Emerging and Zoonotic Infectious Diseases, established in 2010 to address threats like H1N1 influenza, which infected an estimated 60 million Americans in 2009. These evolutions prioritized data-driven surveillance, with annual budgets for specialized centers exceeding $7 billion by 2018, though critics noted mission creep into non-core areas like gun violence research.

COVID-19 Response and Policy Shifts (2019–2022)

The Centers for Disease Control and Prevention (CDC) first became aware of a novel coronavirus outbreak in Wuhan, China, in late December 2019 through international surveillance networks, with the agency issuing a Level 1 travel notice on January 6, 2020, and confirming the first U.S. case on January 21, 2020, in Washington State. Initial response efforts emphasized contact tracing and laboratory development, but were immediately undermined by the agency's distribution of a flawed PCR test kit on February 5, 2020, which suffered from manufacturing defects including contamination in two of three Atlanta labs, leading to up to 33% failure rates in detecting the virus. A 2023 HHS Office of Inspector General report attributed the failure to internal control weaknesses, such as inadequate validation and rushed production without full quality checks, delaying nationwide testing by weeks and hindering early containment amid exponential spread. Preventive guidance evolved rapidly but inconsistently, reflecting shifting interpretations of transmission dynamics. In February and early March 2020, the CDC advised against masks for the general public, stating on February 29 that they were unnecessary for healthy individuals to prevent acquisition, prioritizing reserves for healthcare workers amid shortages. On April 3, 2020, this reversed to recommend cloth masks for all over age 2 in public settings, citing emerging evidence of asymptomatic and presymptomatic spread, though a 2021 CDC-published study in Emerging Infectious Diseases later estimated asymptomatic cases contributed minimally (under 1% in modeled scenarios) to overall transmission. Early emphasis on surface transmission led to extensive disinfection protocols, but by 2021, the CDC deprioritized fomites after data showed negligible risk, redirecting focus to airborne aerosols and ventilation—measures initially underemphasized despite prior knowledge from SARS-1. School policies exemplified prolonged caution, with CDC modeling from March 2020 suggesting closures of eight weeks or longer could reduce community spread more effectively than shorter durations, influencing widespread shutdowns lasting into 2021 despite low pediatric hospitalization rates (under 0.1% for children under 18 by mid-2020). Guidance urged layered mitigations like distancing and masks for in-person learning, but hybrid or remote models persisted in many districts under CDC-influenced metrics tying reopenings to low case thresholds, even as evidence mounted of minimal child-to-adult transmission. By summer 2021, updated frameworks prioritized reopening with mitigations, acknowledging developmental harms from extended closures, though implementation varied. Vaccine rollout accelerated under CDC oversight after FDA emergency use authorizations in December 2020 for Pfizer-BioNTech and Moderna mRNA vaccines, with initial guidance framing two doses as conferring high protection against infection (over 90% efficacy in trials). By mid-2021, breakthrough infections prompted shifts: the CDC acknowledged vaccines primarily reduced severe outcomes rather than stopping transmission, leading to booster endorsements in September 2021 for high-risk groups despite trial data showing waning antibody responses after six months. Policy extended to mandates, with the agency supporting employer and school requirements, but by early 2022, guidance relaxed for vaccinated individuals in low-transmission areas, reflecting variant-driven adaptations like Omicron's immune evasion. These changes, while adaptive, fueled perceptions of overreach, as initial absolute claims eroded amid real-world data showing limited herd immunity effects.

Post-Pandemic Reforms and Declining Trust (2023–2024)

In May 2023, CDC Director Rochelle Walensky announced her resignation, effective June 30, 2023, after leading the agency through the COVID-19 pandemic; she described the move as timed with the nation's transition out of emergency-phase response. Her tenure faced scrutiny for guidance reversals on masks, testing, and transmission risks, as well as internal reviews revealing communication breakdowns, such as delayed data sharing on booster efficacy. President Joe Biden appointed Mandy Cohen, former North Carolina Secretary of Health and Human Services, as successor on June 16, 2023, with Cohen taking office in July to prioritize clearer communication, data-driven decisions, and refocusing on infectious disease prevention over broader social determinants. Cohen initiated reforms to address pandemic-era shortcomings, including an internal reorganization to streamline operations and enhance outbreak preparedness. In April 2024, the CDC released its updated Public Health Data Strategy for 2024–2025, emphasizing modernization of surveillance systems to reduce delays in pathogen detection and integrate real-time analytics for faster response. Guidance updates followed, such as March 2024 revisions to respiratory virus protocols that eliminated COVID-19-specific five-day isolation mandates, instead advising symptom-based precautions akin to those for influenza or RSV, aiming to simplify public adherence and mitigate perceptions of overly restrictive policies. These steps responded to critiques that prior rules contributed to economic and educational disruptions without proportional benefits, though implementation varied by state amid ongoing debates over evidence thresholds. Public trust in the CDC eroded further during this period, with a KFF poll in September 2023 showing overall confidence at around 60%, but only 40% among Republicans—down from 90% in March 2020—linked to partisan divides over school reopenings, vaccine messaging inconsistencies, and perceived alignment with federal overreach. Surveys highlighted broader skepticism, with trust in CDC vaccine information falling to 50% by late 2023 per some metrics, attributed to repeated guidance shifts that undermined perceived scientific consistency. Congressional responses included the 2023 CDC Leadership Accountability Act, mandating Senate confirmation for directors from January 2025 onward to enhance oversight, reflecting demands for accountability amid declining institutional credibility. Cohen publicly acknowledged these trust gaps, pledging transparency initiatives, though polls into 2024 indicated persistent partisan asymmetries, with Democrats retaining higher confidence levels.

Second Trump Administration Changes and 2025 Shooting (2025)

The second Trump administration, inaugurated on January 20, 2025, pursued reforms at the Centers for Disease Control and Prevention (CDC) to realign its focus toward chronic disease prevention, vaccine policy scrutiny, and operational efficiency, often clashing with prior emphases on infectious disease modeling and public health mandates. This included overhauling the childhood vaccine schedule, reducing routine recommendations from 17 diseases to 11 by dropping universal recommendations for RSV, hepatitis B, rotavirus, flu, meningococcal disease, and others, following a federal review led by HHS Secretary Robert F. Kennedy Jr. to align with schedules in other developed nations. On January 31, 2025, CDC leadership directed agency scientists to retract or pause publication of select research manuscripts, citing a need to review alignment with emerging priorities under the Department of Health and Human Services (HHS). In March 2025, HHS Secretary Robert F. Kennedy Jr. announced a departmental overhaul prioritizing interventions against chronic illnesses through improved food safety and reduced reliance on pharmaceutical interventions, which included reallocating CDC resources away from certain global health programs. Leadership upheaval intensified in August 2025, when CDC Director Susan Monarez was removed from her position amid disputes over vaccine guidance and internal resistance to administration directives. Kennedy appointed his deputy, Jim O'Neill, as acting director on August 28, 2025, signaling a shift toward appointees amenable to reevaluating CDC stances on vaccine efficacy and mandates. At least four senior CDC officials resigned shortly thereafter, attributing their departures to pressure from Kennedy to deviate from evidence-based recommendations on vaccination and public health protocols. In October 2025, the administration implemented layoffs affecting dozens of CDC personnel during a partial government shutdown, targeting roles perceived as redundant or ideologically misaligned, though it subsequently rescinded planned cuts to hundreds of scientific positions in response to measles outbreak concerns. These actions drew criticism from public health advocates for potentially undermining institutional expertise, while proponents argued they corrected bureaucratic overreach accumulated under prior administrations. On August 11, 2025, a gunman launched an attack on the CDC's Atlanta headquarters campus, firing approximately 180 rounds from a high-powered rifle, shattering over 150 windows, and causing extensive property damage estimated to require weeks for repairs. The assailant, a Georgia resident who blamed COVID-19 vaccines for his mental health deterioration, killed DeKalb County Police Officer David Rose, who responded to the active shooter alert around 5 p.m., before dying by suicide at the scene. Federal investigators later revealed the shooter had attempted unauthorized entry to the campus two days prior and may have fired up to 500 rounds in total, underscoring vulnerabilities in perimeter security despite post-9/11 enhancements. CDC Director Monarez attributed the incident partly to misinformation about vaccines eroding public trust, stating it had "led to deadly consequences," though the attack highlighted broader tensions over the agency's pandemic-era policies. Kennedy visited the site the following day, pledging enhanced protections for federal health workers amid rising threats linked to polarized debates on public health interventions. Over 750 current and former HHS employees subsequently demanded stronger security measures from Kennedy, citing his public criticisms of CDC practices as potentially exacerbating risks to personnel. The event prompted veterinary and medical associations to express solidarity with affected CDC staff, including those in animal disease divisions impacted by the campus lockdown, and intensified congressional scrutiny of agency funding for physical security.

Organizational Structure

Leadership and Directors

The Centers for Disease Control and Prevention (CDC) is headed by a Director, appointed by the President of the United States and confirmed by the Senate, who serves as the agency's chief executive and primary advisor to the Secretary of Health and Human Services (HHS) on matters of disease prevention, surveillance, and public health response. The Director oversees the Immediate Office, which includes deputy directors for program and science, policy and strategy, and operations, as well as coordination across the CDC's centers, institutes, and offices. This structure ensures alignment with HHS priorities while maintaining operational independence in scientific and epidemiological functions. Historically, CDC directors have been public health experts, often physicians or epidemiologists, with tenures varying based on presidential administrations and agency needs. The role evolved from leadership of the agency's predecessor, the Malaria Control in War Areas (1942–1946), which became the Communicable Disease Center in 1946 and the CDC in 1970. Early directors focused on vector-borne diseases, while later ones addressed emerging threats like HIV/AIDS, Ebola, and pandemics. The following table lists directors from the agency's origins:
DirectorTenureAppointed by
Louis L. Williams1942–1943Franklin D. Roosevelt
Mark D. Hollis1944–1948Harry S. Truman
Raymond A. Vonderlehr1948–1952Harry S. Truman
Justin M. Andrews1952–1956Dwight D. Eisenhower
Theodore J. Bauer1956–1960Dwight D. Eisenhower
Robert J. Anderson1960–1962John F. Kennedy
Clarence A. Smith1962–1966Lyndon B. Johnson
David J. Sencer1966–1977Lyndon B. Johnson
William H. Foege1977–1983Jimmy Carter
James O. Mason1983–1990Ronald Reagan
William L. Roper1990–1993George H. W. Bush
David Satcher1993–1998Bill Clinton
Jeffrey P. Koplan1998–2002Bill Clinton
Julie L. Gerberding2002–2009George W. Bush
Thomas R. Frieden2009–2017Barack Obama
Brenda Fitzgerald2017–2018Donald Trump
Robert R. Redfield2018–2021Donald Trump
Rochelle P. Walensky2021–2023Joe Biden
Mandy K. Cohen2023–2025Joe Biden
Susan Monarez2025 (July–August)Donald Trump
As of October 2025, under the second Trump administration, Jim O'Neil serves as acting CDC Director, having replaced Susan Monarez after her brief tenure. Monarez, a public health researcher, was Senate-confirmed on July 29, 2025 (51–47 vote), and sworn in on July 31 by HHS Secretary Robert F. Kennedy Jr. to advance public health reforms. She was dismissed on August 28, 2025, amid reported internal conflicts over policy direction, with O'Neil—a lawyer and deputy to Kennedy—assuming the acting role effective August 29. This rapid leadership transition reflects ongoing efforts to realign the agency with the administration's "Make America Healthy Again" priorities, including scrutiny of vaccine policies and chronic disease prevention.

Workforce Composition and Training Programs

The Centers for Disease Control and Prevention (CDC) federal workforce consisted of approximately 12,820 civilian employees as of September 2024. Following reforms implemented in 2025 under the second Trump administration, aimed at refocusing the agency on core infectious disease prevention and response, the workforce was reduced by roughly 2,400 positions, with additional cuts of about 600 announced in October 2025, contributing to an overall shrinkage of around 3,000 employees that year. These reductions targeted administrative and non-essential roles, preserving scientific and epidemiological capacity. Workforce composition emphasizes health professionals, with key occupations including epidemiologists, medical officers, laboratory scientists, and public health advisors, alongside administrative and support staff. In 2012, the CDC employed 11,223 federal workers, of whom 61% were women, over 60% were aged 45 or older, and the largest groups were in public health program management, laboratory services, and administrative operations; more recent comprehensive demographic breakdowns for the full agency remain limited in public federal reporting, though subpopulations like the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention saw minority representation rise from 2010 to 2021. The agency's structure includes 10 national centers and offices, distributing personnel across domestic and global health functions, with a emphasis on applied epidemiology over policy or equity-focused roles post-2025 reforms. The CDC's primary training mechanism is the Epidemic Intelligence Service (EIS), a two-year postdoctoral program launched in 1951 to develop applied epidemiology skills through on-the-job fieldwork, outbreak investigations, and surveillance. EIS recruits health professionals such as physicians, nurses, and PhD scientists, assigning them as "disease detectives" to state, local, or international sites for hands-on training in data analysis, rapid response, and public health communication, with graduates often advancing to leadership roles within the CDC or external agencies. The program accepts around 80-100 officers annually, requiring U.S. citizenship, advanced degrees, and commitment to field assignments, and has evolved to include global components while maintaining its focus on infectious disease threats. Complementing EIS, the CDC offers fellowships like the Public Health Fellowship Program and Epidemiology Elective Program for medical students, providing shorter-term training in surveillance, research, and intervention strategies. These initiatives prioritize practical, evidence-based skills over administrative or advocacy training, aligning with the agency's statutory mandate under the Public Health Service Act, though critics have noted historical expansions into non-core areas that were curtailed in 2025 to enhance operational efficiency.

Facilities, Laboratories, and Locations

The Centers for Disease Control and Prevention maintains its primary headquarters on the Roybal Campus in Atlanta, Georgia, at 1600 Clifton Road, which encompasses administrative offices, research centers, and advanced laboratory facilities. This campus includes Biosafety Level 4 (BSL-4) laboratories, the highest containment level for handling pathogens posing severe risks to human health, such as Ebola and smallpox, enabling research on emerging infectious diseases under strict safety protocols. The BSL-4 facilities feature positive-pressure suits and isolated air systems to prevent accidental release. A secondary campus in Chamblee, Georgia, at 4770 Buford Highway, supports the agency's field epidemiology programs, environmental health investigations, and training initiatives, originating from repurposed World War II-era structures. This site houses laboratories focused on non-infectious disease surveillance and public health response coordination. Through the National Institute for Occupational Safety and Health (NIOSH), a component of the CDC, additional specialized laboratories operate across the United States, including in Pittsburgh, Pennsylvania, for respiratory and mining safety research; Morgantown, West Virginia, for engineering and exposure assessment; Cincinnati, Ohio, for chemical toxicology; Spokane, Washington, for agricultural and construction hazards; and Anchorage, Alaska, for cold-weather and vector-borne disease studies in Arctic regions. These facilities conduct applied research to develop protective equipment and standards, with the Pittsburgh site featuring the Arlen Specter Headquarters Building dedicated to high-hazard simulations. The CDC's laboratory network extends domestically via partnerships but maintains core operations in these locations to ensure rapid response capabilities. Internationally, the agency supports over 14,000 partner laboratories in more than 40 countries for capacity building in disease detection, rather than operating standalone facilities abroad.

Budget and Resources

Historical Funding Patterns

The Centers for Disease Control and Prevention (CDC) received its initial federal appropriation of $10 million in 1946, focused on malaria eradication through the Office of Malaria Control in War Areas, which evolved into the Communicable Disease Center. Early funding remained modest, supporting vector control and basic epidemiology, with annual budgets in the tens of millions through the 1950s as the agency's scope expanded to other communicable diseases like polio and tuberculosis under the Public Health Service. By the 1960s and 1970s, appropriations grew to accommodate shifts toward chronic disease surveillance and environmental health, reaching hundreds of millions nominally amid broader public health mandates, though precise annual figures prior to 1980 are sparse in public records. Inflation-adjusted to 2024 dollars, CDC spending stood at approximately $1.02 billion in fiscal year (FY) 1980, reflecting a real increase from post-World War II levels tied to population growth and epidemiological transitions. Subsequent decades saw accelerated growth, with nominal core public health funding rising from under $2 billion in the early 1990s to between $6.5 billion and $8 billion annually from FY2011 to FY2021, punctuated by targeted boosts for HIV/AIDS response in the 1980s (e.g., Ryan White CARE Act allocations) and post-9/11 bioterrorism preparedness (e.g., $1 billion+ via Project BioShield in 2004). The 2010 Affordable Care Act introduced the Prevention and Public Health Fund, providing CDC with mandatory transfers averaging $900 million to $1 billion yearly, supplementing discretionary appropriations from the Labor-HHS-Education bill and enabling expansions into non-communicable risks like obesity and injury prevention. Nominal core funding climbed to $9.269 billion in FY2023 before a slight dip to $9.248 billion in FY2024, with supplemental appropriations—such as $26.4 billion for COVID-19 by early 2023—temporarily inflating totals but not altering base patterns reliant on annual congressional approval. Overall, inflation-adjusted spending reached $12.2 billion in FY2024, a 1,095% real increase from FY1980, outpacing federal spending growth (194%) and correlating with mission broadening beyond infectious diseases, though core discretionary levels stagnated relative to inflation in periods like post-2008 recession and FY2011-FY2021 (1%-6% nominal annual changes, excluding sequestration cuts). This trajectory underscores funding dependence on episodic threats and legislative priorities, with limited user fees or non-federal sources comprising under 5% historically.

Current Allocations and Fiscal Challenges (as of 2025)

As of fiscal year 2025, the Centers for Disease Control and Prevention (CDC) operates under a constrained budget framework inherited from prior years but subject to immediate executive actions under the second Trump administration, including staff reductions and funding reallocations prioritizing core disease surveillance over expanded programmatic scopes. The baseline FY 2025 appropriation, prior to adjustments, aligned with congressional justifications totaling approximately $9.683 billion, supporting activities in outbreak response, infrastructure, and chronic disease prevention. However, implementation has been disrupted by government shutdown contingencies and administrative directives, with new appropriations limited to around $639 million in select accounts amid broader fiscal tightening. Significant fiscal challenges emerged in 2025, driven by workforce attrition and targeted funding withholdings. The administration enacted layoffs affecting over 1,000 CDC personnel in October, framed as responses to shutdown risks, followed by additional cuts projecting a further 1,100 positions, reducing total staff toward 10,300 from pre-2025 levels. These measures, including a prior plan eliminating 2,400 roles with partial reinstatements of about 700, reflect efforts to address perceived bureaucratic expansion post-COVID-19, though they have strained operational capacity in areas like the Epidemic Intelligence Service. Overall, such reductions equate to roughly a quarter of the workforce lost via layoffs, buyouts, and resignations, exacerbating vulnerabilities during ongoing health threats. Funding delays and blocks compounded these issues, with the administration withholding 2025 allocations for health research and public health programs, mirroring patterns of fiscal restraint to curb non-essential expenditures. Proposed FY 2026 budgets signal deeper cuts, potentially reducing CDC funding by 42-53%—from about $9.2 billion to $4.3 billion—and eliminating over 60 programs, including those for chronic illness prevention and global initiatives, to redirect resources toward immediate domestic outbreak control. These reforms, led by HHS Secretary Robert F. Kennedy Jr., aim to eliminate redundancies but have drawn criticism for risking surveillance gaps, as evidenced by reduced participation in disease conferences amid shutdowns. Reports from outlets like The Guardian and CNN highlight potential threats to chronic disease tracking, though such sources often emphasize program preservation over efficiency gains. Senate resistance to some cuts preserved portions of funding, approving around $9.3 billion in committee proposals, underscoring congressional pushback against executive overreach.

Core Functions and Programs

Disease Surveillance Systems and Datasets

The Centers for Disease Control and Prevention (CDC) maintains multiple surveillance systems to track infectious diseases, chronic conditions, vital events, and emerging health threats, enabling timely public health responses through data aggregation from state, local, and territorial jurisdictions. These systems rely on voluntary reporting, electronic data submissions, and standardized case definitions, with the CDC providing technical support via platforms like the National Electronic Disease Surveillance System Base System (NBS), which facilitates secure data exchange for over 50 jurisdictions. Data from these systems inform national estimates, outbreak detection, and policy, though provisional figures are subject to revision as jurisdictions finalize reports, potentially leading to discrepancies in early assessments. The National Notifiable Diseases Surveillance System (NNDSS), established as a collaborative framework since the 1960s and formalized in its current structure by the 1990s, compiles weekly provisional and annual finalized data on approximately 120 nationally notifiable conditions, including infectious diseases like anthrax, botulism, and COVID-19. State health departments report cases meeting standardized surveillance case definitions, which the CDC updates annually via the Council of State and Territorial Epidemiologists (CSTE); for instance, in 2025, conditions encompass arboviral diseases and babesiosis among others. This system supports monitoring trends, such as the weekly MMWR tables tracking incidence rates, but depends on jurisdictional completeness, with underreporting possible for mild or asymptomatic cases due to voluntary participation. The Behavioral Risk Factor Surveillance System (BRFSS), launched in 1984, conducts annual state-based telephone surveys of over 400,000 U.S. adults to assess health-related risk behaviors, chronic health conditions, and preventive practices, generating the largest continuously collected health survey dataset globally. Data cover topics like tobacco use, physical inactivity, and obesity prevalence, with state-specific estimates weighted for demographic representativeness; for example, 2023 prevalence data revealed varying hypertension rates across states. While effective for tracking non-communicable disease risks, BRFSS relies on self-reported responses, which can introduce recall bias, and excludes institutionalized populations, limiting generalizability. The National Vital Statistics System (NVSS), operational since 1902 through partnerships with state vital registration offices, provides comprehensive, population-based data on all U.S. births, deaths, marriages, and divorces, including cause-of-death coding via ICD-10 for over 2.8 million annual death records. Mortality datasets track disease-specific fatalities, such as leading causes like heart disease (accounting for about 695,000 deaths in 2021), enabling national life expectancy calculations and trend analysis. NVSS data achieve near-complete coverage due to legal reporting requirements but face delays in processing (up to 11 months for final files) and potential miscoding errors in cause attribution. Additional systems include the National Syndromic Surveillance Program (NSSP), which analyzes real-time emergency department and other syndromic data from over 80% of U.S. hospitals for early outbreak detection, processing millions of records daily to identify anomalies like respiratory illness spikes. CDC datasets from these systems are publicly accessible via data.cdc.gov and tools like WONDER, encompassing COVID-19 case surveillance (over 100 million records since 2020) and chronic disease indicators, though some portals faced temporary offline periods in early 2025 amid administrative reviews. Accuracy evaluations highlight strengths in timeliness for syndromic data but note challenges like incomplete EHR integration and pathogen-specific reductions, as seen in the 2025 scaling back of foodborne illness monitoring from eight to two pathogens.

Communicable Disease Control

The Centers for Disease Control and Prevention (CDC) maintains primary responsibility for domestic surveillance, prevention, and response to communicable diseases in the United States, originating from its establishment in 1946 as the Communicable Disease Center to assist states in controlling outbreaks such as malaria and typhus. This mandate encompasses bacterial, viral, parasitic, and zoonotic infections, with operations coordinated through centers like the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), which focuses on early detection and containment to mitigate transmission. CDC guidelines emphasize evidence-based interventions, including contact tracing, isolation protocols, and antimicrobial stewardship, informed by epidemiological data rather than unverified models. A cornerstone of CDC's efforts is the National Notifiable Diseases Surveillance System (NNDSS), which aggregates weekly and annual reports of over 120 infectious conditions from state and local health departments, enabling real-time monitoring of incidence trends and outbreak signals. Established under the Council of State and Territorial Epidemiologists, NNDSS data underpin public health actions, such as declaring measles outbreaks in 2019 with 1,282 confirmed U.S. cases linked to international importation, prompting targeted vaccination drives. Complementary systems like the Emerging Infections Program track antimicrobial-resistant pathogens and foodborne illnesses across 14 network sites, providing population-based incidence rates—for instance, estimating 48 million annual foodborne infections in the U.S. to guide regulatory responses. In outbreak response, CDC deploys multidisciplinary teams for field investigations, laboratory confirmation, and containment, as demonstrated in the 2014-2016 Ebola response where over 4,000 personnel supported contact tracing and biosafety protocols, reducing imported cases through enhanced airport screening. The Global Rapid Response Team, operational since 2015, facilitates international deployments to 67 countries, aiding detection of nearly 6,000 outbreaks by 2025 via genomic sequencing and epidemiological modeling. Domestically, CDC coordinates with the Department of Health and Human Services under the Public Health Emergency framework, issuing isolation orders and distributing countermeasures, though effectiveness depends on state compliance and pathogen transmissibility. Prevention strategies prioritize vaccination programs, which CDC oversees through the Advisory Committee on Immunization Practices, recommending schedules that have averted an estimated 472 million illnesses and 1.1 million deaths from diseases like measles and polio since 1980. For tuberculosis, CDC funds state programs achieving a 80% decline in U.S. cases since 1992 via directly observed therapy, targeting latent infections with isoniazid prophylaxis. HIV control involves PrEP distribution and viral load monitoring, reducing new diagnoses by 18% from 2015 to 2022, while sexually transmitted infection initiatives emphasize partner notification over broad screening due to variable efficacy. These efforts integrate causal factors like pathogen R0 values and herd immunity thresholds, derived from longitudinal cohort studies rather than consensus-driven narratives. Notable achievements include contributions to global smallpox eradication certified in 1980, where CDC-led vaccination campaigns and surveillance eliminated the last U.S. case in 1949, and near-elimination of polio through oral vaccine distribution, preventing 20 million cases worldwide from 1988 to 2024 via partnerships. However, resurgences like pertussis outbreaks exceeding 48,000 U.S. cases in 2012 highlight vaccination hesitancy's role in waning immunity, underscoring the need for ongoing serological monitoring over reliance on historical precedents. CDC's empirical tracking has also curbed vector-borne diseases, such as reducing West Nile virus neuroinvasive cases from 986 in 2003 to under 200 annually by 2020 through insecticide applications and blood donor screening.

Non-Communicable Diseases and Risk Factors

The National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) within the CDC coordinates efforts to prevent and manage non-communicable diseases (NCDs), including heart disease, cancer, type 2 diabetes, stroke, chronic obstructive pulmonary disease, and obesity-related conditions, which account for the majority of preventable deaths in the United States. These initiatives emphasize addressing modifiable risk factors such as tobacco use, poor nutrition, physical inactivity, excessive alcohol consumption, and uncontrolled high blood pressure through evidence-based public health strategies. NCCDPHP supports state, local, tribal, and territorial health departments via funding, technical assistance, and policy guidance to implement community-level interventions. Key divisions under NCCDPHP target specific NCDs and risks. The Division of Nutrition, Physical Activity, and Obesity promotes environmental changes to encourage healthy eating and active lifestyles, funding state programs that have reached millions to combat obesity, a risk factor for type 2 diabetes, heart disease, and certain cancers. The Division for Heart Disease and Stroke Prevention focuses on blood pressure management, supporting initiatives that have helped reduce cardiovascular events through screening and medication adherence programs. The National Diabetes Prevention Program, a lifestyle intervention for prediabetic adults, has demonstrated a 58% reduction in type 2 diabetes incidence in participants aged 60 and older, with a nationwide network of over 2,000 recognized providers as of 2024. In cancer prevention, the Division of Cancer Prevention and Control administers the National Comprehensive Cancer Control Program, established in 1998, which funds 65 coalitions to develop state-specific plans reducing cancer incidence through tobacco control, screening, and risk reduction, alongside the National Breast and Cervical Cancer Early Detection Program serving over 300,000 low-income women annually. Surveillance underpins these efforts, with the Behavioral Risk Factor Surveillance System (BRFSS), launched in 1984, providing annual state-level data on NCD risk behaviors from over 400,000 U.S. adults via telephone surveys, informing prevalence estimates for smoking (11.5% in 2022), obesity (32.2% in 2022), and physical inactivity. The Chronic Disease Indicators portal aggregates these and other datasets to track NCD burden, enabling targeted resource allocation. Globally, CDC's Noncommunicable Disease Unit supports NCD surveillance and training, including Field Epidemiology Training Program tracks established in 2018 in countries like China and India to build capacity for risk factor monitoring and premature mortality reduction, aligning with UN Sustainable Development Goals.

Global Health and International Efforts

The Centers for Disease Control and Prevention (CDC) operates a Global Health Center that coordinates efforts to mitigate infectious disease threats originating abroad, emphasizing prevention, detection, and response to protect U.S. public health interests. Established to address transnational health risks, the center maintains operations in over 60 countries, collaborating with foreign ministries of health to build surveillance systems and laboratory capacity. These activities focus on high-burden conditions such as HIV/AIDS, tuberculosis, malaria, and emerging pathogens, with funding often tied to U.S. foreign assistance programs that prioritize containment of threats before they reach American borders. A cornerstone of CDC's international work is the Field Epidemiology Training Program (FETP), which has trained thousands of public health professionals in applied epidemiology across more than 80 countries since its global expansion in the 1980s. Participants engage in hands-on outbreak investigations, data analysis, and response strategies, enhancing host nations' abilities to detect and control epidemics independently. This program aligns with the Global Health Security Agenda (GHSA), launched in 2014 as a multinational framework involving over 70 partners to strengthen compliance with the World Health Organization's International Health Regulations (2005), which mandate rapid reporting and response to public health emergencies of international concern. CDC contributes technical expertise to international outbreak responses, including deployments for the 2014–2016 West Africa Ebola epidemic, where it supported contact tracing and laboratory diagnostics in affected regions; the 2015–2017 Zika virus spread in the Americas, aiding vector control and congenital syndrome monitoring; and early COVID-19 investigations in Wuhan, China, in January 2020, though subsequent domestic response critiques highlighted coordination challenges with global partners. These efforts underscore CDC's role in the WHO-led Vaccine Safety Net and pharmacovigilance networks, providing data on vaccine efficacy and adverse events from field operations. Despite achievements in averting cross-border transmissions, evaluations have noted dependencies on U.S. funding and occasional tensions with host governments over data sovereignty.

Vaccine Safety, Policy, and Monitoring

The Centers for Disease Control and Prevention (CDC) plays a central role in formulating U.S. vaccine policy through the Advisory Committee on Immunization Practices (ACIP), which develops evidence-based recommendations on vaccine use for disease control. ACIP, comprising medical and public health experts, evaluates clinical data, efficacy, safety profiles, and cost-effectiveness to specify target populations, dosing schedules, and contraindications; these recommendations, once adopted by the CDC director, guide federal purchasing, insurance reimbursement under the Affordable Care Act, and state-level mandates for school entry. For instance, ACIP's June 2025 update shifted COVID-19 vaccination recommendations for individuals aged 6 months and older to shared clinical decision-making rather than universal endorsement, reflecting evolving data on baseline immunity and risk stratification. In January 2026, ACIP overhauled the routine childhood immunization schedule, reducing recommendations from 17 diseases to 11 by dropping vaccines for RSV, hepatitis B, rotavirus, influenza, meningococcal disease, and others, following a federal review to align with schedules in other developed nations. CDC vaccine safety monitoring relies on a multi-tiered system combining passive and active surveillance to detect potential adverse events following immunization (AEFIs). The Vaccine Adverse Event Reporting System (VAERS), co-administered with the Food and Drug Administration (FDA) since 1990, serves as a national early warning mechanism, accepting voluntary reports from healthcare providers, vaccine recipients, and manufacturers on any health issues post-vaccination. As of May 2025, VAERS data analysis remains foundational for signal detection but cannot establish causality, with acknowledged underreporting—estimated at less than 1% for serious events in some CDC studies—and reliance on follow-up investigations to validate signals. Complementing VAERS, the Vaccine Safety Datalink (VSD), established in 1990, enables active surveillance through electronic health records from nine integrated healthcare organizations covering over 10 million individuals, facilitating rapid cohort studies on specific risks like Guillain-Barré syndrome after influenza vaccines or myocarditis following mRNA COVID-19 doses. During the COVID-19 pandemic from 2020 to 2025, CDC expanded monitoring with V-safe, a smartphone app for real-time self-reporting of symptoms among over 10 million users, which identified common mild reactogenicity but also contributed to detecting rare signals such as anaphylaxis rates of 2.5-11.1 per million doses for mRNA vaccines. Empirical analyses from VSD and other systems affirmed overall vaccine safety, with COVID-19 shots averting millions of hospitalizations and deaths while associating elevated myocarditis risk (peaking at 40-60 cases per million second doses in young males) that resolved in most cases without long-term sequelae. Critics, including analyses in peer-reviewed outlets, have highlighted systemic flaws in these mechanisms, such as VAERS's passive design leading to incomplete data processing and delays in public release, potentially obscuring signals during high-volume reporting periods like 2021's surge of over 1 million COVID-related submissions. A 2023 BMJ investigation described VAERS as "broken" due to understaffing, opaque follow-up protocols, and failure to promptly investigate clustered reports, though CDC maintains the system's signals prompted actions like pausing the Janssen COVID-19 vaccine in April 2021 over thrombosis concerns. VSD studies, while more robust, face limitations from participating sites' demographic skews and potential diagnostic biases in electronic records, underscoring the need for independent verification of post-licensure safety claims.

Publications and Communication

Key Journals and Reports

The Morbidity and Mortality Weekly Report (MMWR) series serves as the Centers for Disease Control and Prevention's (CDC) primary vehicle for disseminating timely, reliable, and authoritative public health information, including surveillance data on notifiable infectious diseases, outbreak investigations, and clinical recommendations. Originating from bulletins dating back to July 13, 1878, under the U.S. Public Health Service, the publication was renamed MMWR in 1952 and integrated into CDC operations by 1960, evolving into a weekly format that compiles provisional morbidity data from state health departments. MMWR reports have historically played a pivotal role in alerting practitioners to emerging threats, such as the 1981 identification of AIDS cases, influencing rapid public health responses through evidence-based summaries rather than peer-reviewed articles. Emerging Infectious Diseases (EID), a peer-reviewed, open-access journal published monthly by the CDC since 1995, focuses on the epidemiology, prevention, and control of infectious diseases with potential for global spread. It features original research, policy analyses, and perspectives on topics like antimicrobial resistance and zoonotic pathogens, aiming to bridge gaps between laboratory science and field epidemiology. Unlike MMWR's emphasis on rapid reporting, EID undergoes rigorous peer review to publish in-depth studies, contributing to international discourse on disease emergence, as evidenced by its coverage of outbreaks like SARS and Ebola. Beyond these flagship publications, the CDC produces specialized reports through its National Center for Health Statistics (NCHS), including the Vital Statistics Rapid Release series, which provides provisional data on births, deaths, and causes of mortality to enable real-time health trend analysis. Annual summaries of nationally notifiable diseases, derived from the National Notifiable Diseases Surveillance System (NNDSS), are integrated into MMWR's year-end compilations, offering comprehensive tabulations of incidence rates for conditions like tuberculosis and measles. These reports prioritize empirical surveillance over interpretive narrative, though their provisional nature requires subsequent validation against finalized datasets.

Data Dissemination and Transparency Issues

The Centers for Disease Control and Prevention (CDC) has faced significant criticism for delays and selective dissemination of raw data, particularly during the COVID-19 pandemic, which impeded independent analysis and public scrutiny. For instance, from early 2020 through much of 2021, the CDC collected detailed hospitalization data segmented by age, race, vaccination status, and other demographics but refrained from publishing much of it, citing concerns over potential misinterpretation by the public or media. CDC Director Rochelle Walensky confirmed in February 2022 that the agency had withheld portions of this data for over a year, arguing it was not "serving an important purpose right now" amid evolving variants and vaccination rates, though she pledged fuller releases thereafter. This approach drew rebukes for prioritizing narrative control over transparency, as external researchers and policymakers relied on incomplete datasets that obscured trends like breakthrough infections among the vaccinated, which constituted a growing share of cases by mid-2021. Further compounding these issues, the CDC altered reporting methodologies in ways that obscured vaccine effectiveness metrics; for example, in February 2021, it shifted from absolute risk reductions to relative reductions in its communications, and by July 2021, it ceased routine publication of detailed vaccinated versus unvaccinated hospitalization rates as the vaccinated population dominated, making unadjusted comparisons appear less favorable to vaccination narratives. Critics, including members of Congress, argued this selective framing undermined causal assessments of policy impacts, such as school closures or mask mandates, where raw data on child transmission rates—often low despite high case volumes—were not promptly shared, contributing to prolonged restrictions. The agency's Vaccine Adverse Event Reporting System (VAERS) data, while publicly accessible, has been disseminated with heavy caveats emphasizing underreporting and correlation-not-causation, yet CDC analyses often downplayed signals like myocarditis risks in young males post-mRNA vaccination until external pressure from Israel and Europe in June 2021 prompted updates. These practices have eroded public trust, with CDC's own assessments attributing declines to "inconsistent messaging" and "lack of transparency" as of September 2025. In response, the agency has initiated internal reforms, such as modernizing data hygiene for faster iterations during crises, but persistent barriers like privacy regulations and resource constraints continue to delay releases, as evidenced by state-level complaints over fragmented COVID-19 surveillance data transitions to HHS Protect in 2020-2022. Independent reviews highlight that without real-time, unredacted access, epidemiological decisions risk bias toward institutional consensus rather than empirical validation, a concern amplified by the CDC's role in influencing global health policies through partnerships like those with the World Health Organization. Overall, these dissemination shortcomings have fueled demands for statutory mandates requiring raw data publication within fixed timelines, akin to financial disclosure rules, to restore credibility.

CDC Foundation

Establishment and Activities

The CDC Foundation was authorized by the United States Congress through legislation enacted in 1992, establishing it as an independent nonprofit organization to support the Centers for Disease Control and Prevention (CDC) in advancing public health initiatives. Formally incorporated as a 501(c)(3) public charity in 1995, the Foundation operates separately from the federal government while aligning its efforts with CDC priorities to leverage private resources for disease prevention and control. Its statutory purpose, as defined in 42 U.S.C. § 280e-11, is to support activities aimed at preventing and controlling diseases, disorders, injuries, and disabilities, including through partnerships that the CDC cannot directly pursue due to federal restrictions. Since its inception, the Foundation has focused on bridging gaps in public health funding and implementation by facilitating collaborations between the CDC, private sector entities, philanthropists, and international partners. It has raised over $2.2 billion in contributions and launched more than 1,450 programs addressing chronic conditions such as cardiovascular disease and cancer, infectious threats including malaria and HIV, and emergency responses to outbreaks like Ebola, Zika, and COVID-19. Key activities include program management, such as deploying rapid workforce surges for pandemic testing and contact tracing, and targeted initiatives like the How Right Now campaign for mental health support during COVID-19. The Foundation also supports global health efforts, including vaccine distribution and disease surveillance in low-resource settings, often by channeling funds to CDC-led projects without direct federal appropriation. Operational activities emphasize efficiency in grant-making and partnership-building, with the Foundation acting as a conduit for non-governmental resources to accelerate CDC objectives, such as tobacco control, opioid crisis response, and hurricane disaster relief. By 2024, these efforts had enabled implementation of over 1,400 distinct health interventions, demonstrating a model of supplemental support that extends beyond traditional government funding mechanisms.

Funding Sources and Potential Conflicts

The CDC Foundation, established as a 501(c)(3) nonprofit in 1995, derives its funding predominantly from private charitable contributions, philanthropic grants, and partnerships with individuals, corporations, and foundations, rather than direct federal appropriations. In fiscal year 2021, total contributions reached $463 million, with $317 million allocated specifically to COVID-19 response efforts channeled through the Foundation to CDC programs. Recent donor reports highlight support from entities such as the Robert Wood Johnson Foundation, Vitamix Foundation, and the National Association of Chain Drug Stores, alongside individual and corporate gifts categorized by levels like "Champions" ($10,000+) and "Ambassadors" ($5,000–$9,999). The Foundation incorporates an administrative fee of approximately 16% into grants to cover operational costs, with funds ultimately supporting CDC initiatives after review for alignment with public health goals. Corporate and industry donations form a significant portion of revenue, enabling rapid-response funding for outbreaks and surveillance but prompting scrutiny over potential influences on policy. For example, the Foundation has accepted multimillion-dollar gifts from pharmaceutical companies to support vaccine distribution, infectious disease tracking, and public awareness campaigns, including flu prevention efforts like the "Take 3" initiative partially funded by industry sponsors. Similarly, donations from non-health sectors, such as beverage giants like Coca-Cola for anti-obesity programs, drew criticism for possible bias in nutritional guidelines, leading the Foundation to sever ties with such donors in 2018 amid congressional pressure for greater donor transparency. These funding dynamics have fueled concerns about conflicts of interest, as private entities providing unrestricted or program-specific grants may indirectly shape CDC priorities toward donor-aligned areas, such as vaccine promotion or chronic disease management, potentially at the expense of independent oversight. The Foundation's guidelines require CDC evaluation of gifts for perceived conflicts, prohibiting direct influence on decisions, yet critics argue that opaque donor lists and the scale of industry contributions—exacerbated during emergencies like COVID-19—erode public trust by blurring lines between philanthropy and regulatory capture. In fiscal year 2023, the Foundation transferred about $13.5 million to CDC, underscoring its role as a conduit but highlighting the need for rigorous disclosure to mitigate risks of undue influence from profit-driven stakeholders.

Achievements and Impacts

Major Public Health Victories

The Centers for Disease Control and Prevention (CDC) has played a pivotal role in advancing public health through targeted disease surveillance, vaccination initiatives, and eradication campaigns, leading to substantial reductions in morbidity and mortality from infectious diseases in the United States and globally. Established in 1946 as the Communicable Disease Center, the agency prioritized vector-borne diseases like malaria, achieving its domestic eradication by 1951 through coordinated insecticide use, drainage projects, and surveillance that screened over 144 million blood samples and treated millions of cases. This effort eliminated malaria as an endemic threat in the U.S., preventing an estimated annual toll of thousands of deaths and cases that persisted into the early 20th century. A landmark global victory attributable to CDC involvement was the eradication of smallpox, certified by the World Health Organization in 1980 after no cases were reported since 1977. The CDC contributed technical guidance, vaccine production oversight, training for international teams, and epidemiological support starting from its 1962 smallpox surveillance unit, which evolved into leadership in the Intensified Smallpox Eradication Program alongside the WHO. This campaign vaccinated over 80% of populations in endemic areas, averting 300–500 million deaths worldwide in the 20th century alone. In vaccination programs, CDC efforts drove the elimination of indigenous poliovirus transmission in the Americas by 1994, as certified by the Pan American Health Organization, via mass immunization drives using oral polio vaccine that reached 80–90% coverage in key regions and integrated surveillance detecting zero wild poliovirus cases after 1991. Domestically, routine childhood immunizations recommended and monitored by the CDC have prevented over 500 million illnesses and 32 million hospitalizations among U.S. children born 1994–2023, with measles cases dropping 99% from pre-vaccine eras due to sustained vaccination rates above 90% in many communities. These successes stemmed from CDC's development of the Vaccines for Children program in 1994, which provided free vaccines to uninsured children, immunizing over 130 million doses annually by the 2010s.

Long-Term Effects on Disease Burden

The Centers for Disease Control and Prevention (CDC) has significantly reduced the U.S. and global burden of infectious diseases through vaccination programs, surveillance systems, and eradication efforts, leading to millions of prevented cases, hospitalizations, and deaths over decades. Routine childhood immunizations recommended by the CDC, implemented since the mid-20th century, have averted approximately 508 million illnesses, 32 million hospitalizations, and 1.1 million premature deaths among children born between 1994 and 2023 in the United States alone. These outcomes stem from causal interventions like widespread vaccine deployment, which directly lowered incidence rates for vaccine-preventable diseases by interrupting transmission chains, as evidenced by historical morbidity data showing near-elimination of endemic cases for diseases such as polio and measles. Key achievements include the global eradication of smallpox in 1980, a milestone led by CDC epidemiologists who coordinated intensified vaccination campaigns starting in 1966, reducing annual deaths from an estimated 2 million in 1967 to zero worldwide. In the U.S., CDC-driven polio vaccination efforts eliminated indigenous wild poliovirus transmission by 1979, dropping reported cases from 21,269 in 1952 to zero thereafter. Similarly, measles incidence fell from 3-4 million annual U.S. cases in the pre-vaccine era (before 1963) to fewer than 100 per year by the 1980s, sustained through herd immunity thresholds achieved via CDC-supported immunization schedules. These reductions have compounded into long-term decreases in disability-adjusted life years (DALYs) lost to infectious diseases, with vaccines accounting for a substantial portion of the observed decline in child mortality from such causes.
DiseasePre-Vaccine Era Annual U.S. Cases (Approximate)Post-Elimination/Eradication StatusSource
SmallpoxEndemic until 1949 (last U.S. case)Globally eradicated 1980
Polio21,269 (1952 peak)Eliminated in U.S. 1979
Measles3-4 million<100 annually by 1980s
Diphtheria175,000-200,000 (1920s-1930s)Near zero since 1980
Pertussis200,000Reduced >90% from peak
CDC's global initiatives, including technical support for the Expanded Programme on Immunization (EPI) launched in 1974, elevated worldwide vaccination coverage from under 20% in 1980 to nearly 80% by 1990, contributing to broader reductions in disease burden beyond U.S. borders. Ongoing surveillance has enabled rapid outbreak containment, preventing resurgence and maintaining low endemicity, though recent coverage dips highlight vulnerabilities to incomplete adherence. Overall, these efforts demonstrate a causal link between CDC interventions and diminished long-term disease burden, quantified in averted morbidity and mortality that outweigh baseline improvements from sanitation or nutrition alone for targeted pathogens.

Controversies and Criticisms

Tuskegee Syphilis Study Legacy

The U.S. Public Health Service Syphilis Study at Tuskegee, conducted from 1932 to 1972, enrolled 600 African American men in Macon County, Alabama—399 with untreated syphilis and 201 without—to observe the disease's natural progression without providing effective treatment, even after penicillin became available in the 1940s. Participants received no informed consent and were deceived with promises of free medical care for "bad blood," leading to unnecessary suffering, including blindness, insanity, and death in over 100 cases, while autopsies were performed on many to study disease effects. Although initiated by the USPHS before its evolution into the CDC in 1946, the study persisted under federal public health auspices, with CDC inheriting institutional responsibility for its ethical lapses. The study's exposure in 1972 by whistleblower Peter Buxtun prompted immediate termination and catalyzed major ethical reforms in human subjects research, including the 1974 National Research Act, which mandated institutional review boards (IRBs) and informed consent protocols for federally funded studies. This led to the 1979 Belmont Report, articulating principles of respect for persons, beneficence, and justice, fundamentally reshaping U.S. research standards to prevent deception and exploitation. For the CDC, the legacy enforced stricter oversight in its epidemiological studies, though critics note that pre-existing guidelines were ignored, highlighting failures in enforcement rather than absence of rules. Public trust in public health institutions, particularly the CDC, suffered enduring damage, especially among African American communities, fostering perceptions of systemic racism and experimentation that correlate with lower research participation rates and heightened vaccine hesitancy. Empirical studies show mixed evidence on the direct causal impact, with some surveys indicating that while awareness of Tuskegee is high (over 60% among Black Americans), its influence on health behaviors may be overstated compared to broader historical traumas like slavery or segregation. The CDC responded with a 1997 presidential apology from Bill Clinton, survivor benefits, and ongoing remembrance programs, yet persistent mistrust—evident in lower COVID-19 vaccination rates among Black adults (around 10-15% gaps versus whites)—underscores unresolved credibility issues tied to this episode.

Expansion into Social and Political Advocacy (e.g., Gun Violence)

In the 1980s and early 1990s, the CDC expanded its injury prevention efforts to include firearm-related violence, allocating about $2.6 million annually by the early 1990s for internal and external studies on guns as a public health issue. This initiative framed intentional shootings—primarily homicides and suicides—as preventable through epidemiological methods akin to disease control, emphasizing data collection on injury mechanisms and risk factors. However, following CDC Director David Sencer's testimony linking gun availability to violence rates, Congress enacted the Dickey Amendment in 1996 as part of an appropriations bill, barring the use of funds "in whole or in part" for the advocacy of gun control, which was broadly interpreted to halt most federal firearm research. The restriction persisted until the 2012 Sandy Hook Elementary School shooting prompted President Barack Obama to issue executive orders directing the CDC to research gun violence causes and solutions, bypassing the amendment's intent by focusing on "prevention" rather than control advocacy. Congress clarified in 2018 that the Dickey Amendment prohibited only advocacy, not factual research, enabling renewed funding; starting in fiscal year 2020, lawmakers appropriated $25 million annually—$12.5 million each to the CDC and National Institutes of Health—for studies on firearm injury prevention. By 2024, the CDC described firearm violence as a "serious public health problem" impacting health and safety, publishing data on over 48,000 annual U.S. firearm deaths (including about 27,000 suicides and 20,000 homicides) and promoting interventions like safe storage, community programs, and policy supports for background checks and red-flag laws. This shift has drawn criticism for constituting mission creep, as the CDC's statutory focus on communicable diseases and vital statistics has been stretched to encompass non-contagious intentional acts, potentially diluting resources for core threats like infectious outbreaks. Detractors argue the public health model overlooks causal realities—such as criminal intent, socioeconomic drivers, and defensive gun uses (estimated at 500,000 to 3 million annually by some surveys)—while prioritizing regulatory interventions that align with gun restriction policies, raising concerns of politicization amid partisan divides on Second Amendment issues. Sources advocating this expansion, often from academia or progressive organizations, may reflect institutional biases favoring policy-oriented research, whereas empirical trends show gun homicide rates fluctuating with urban crime patterns rather than firearm ownership levels alone, challenging epidemic analogies to transmissible diseases. Such advocacy has fueled perceptions of the CDC overstepping into legislative territory, contributing to broader debates on agency overreach.

COVID-19 Handling: Guidance, Data Practices, and Mandates

The CDC's initial response to the COVID-19 outbreak in early 2020 was hampered by the failure of its diagnostic test kit, which was distributed despite known contamination issues stemming from internal control weaknesses, including improper lab practices and inadequate quality assurance. A U.S. Department of Health and Human Services Office of Inspector General review found that CDC officials proceeded with release on February 5, 2020, even after detecting a high failure rate in one of the kit's components, delaying nationwide testing capacity by weeks and contributing to undetected community spread. This misstep, as documented in CDC's own retrospective analysis, positioned the agency as the sole testing provider initially, exacerbating surveillance gaps during a period of exponential viral growth. Guidance on non-pharmaceutical interventions evolved amid emerging data but featured notable inconsistencies. In February 2020, CDC advised against masks for the general public to conserve supplies for healthcare workers, shifting to universal indoor masking recommendations by July 14, 2020, based on evidence of asymptomatic transmission. School closure guidance, issued March 16, 2020, encouraged widespread shutdowns without robust age-stratified risk data, leading to prolonged disruptions despite later analyses showing minimal pediatric severe outcomes relative to adults. Vaccine recommendations, starting with emergency use authorizations in December 2020, emphasized mRNA platforms for all eligible groups, including children as young as 6 months by June 2022, prioritizing vaccination over natural immunity despite peer-reviewed studies indicating comparable or superior protection from prior infection against reinfection and hospitalization. CDC analyses, such as a 2021 MMWR report, asserted vaccine-induced immunity's consistency over natural immunity, but external critiques highlighted potential overestimation of vaccine durability against variants and underweighting of hybrid immunity data. Data practices faced scrutiny for transparency and methodological shifts. Hospitalization and death surveillance relied on voluntary reporting via systems like COVID-NET, but a July 2020 directive rerouted hospital data from CDC to the Department of Health and Human Services' HHS Protect platform introduced delays and inaccuracies, as hospitals struggled with dual systems and inconsistent metrics for "COVID-related" admissions. Provisional death counts, updated weekly, incorporated "involving COVID-19" certifications prone to overattribution, with a Government Accountability Office assessment noting limitations in distinguishing primary causation amid comorbidities. An external review criticized CDC for underemphasizing long-term threats in data dissemination, potentially skewing public risk perceptions, while internal modernization efforts post-2020 acknowledged legacy system obsolescence exposed by the pandemic. By 2023, CDC transitioned some metrics to wastewater surveillance and variant proportion estimates, but critics argued these masked waning overall burden compared to initial projections. CDC guidance directly informed mandates at federal, state, and institutional levels. Recommendations for vaccine requirements in workplaces and schools, articulated by Director Rochelle Walensky in 2021, supported executive actions like President Biden's September 2021 mandate for federal employees and contractors, affecting over 100 million Americans, though later rescinded amid legal challenges. Mask mandates for public transit, upheld by CDC orders until May 2022, were struck down by courts for overreach, reflecting tensions between agency advisories and enforceable policy. Lockdown-aligned guidance on social distancing and capacity limits, without quantified cost-benefit analyses for economic or mental health impacts, influenced 2020-2021 state emergency declarations, yet retrospective evaluations questioned proportionality given disproportionate harms to non-elderly populations. By October 2025, CDC shifted toward individual-based decision-making for COVID-19 vaccination in updated schedules, diverging from prior universal mandates amid evidence of variant escape and booster fatigue. These practices, while aimed at containment, drew criticism for prioritizing compliance over empirical reassessment of interventions' marginal efficacy as immunity landscapes evolved.

Institutional Bias, Political Influence, and Overreach

The Centers for Disease Control and Prevention (CDC) has faced criticism for institutional bias stemming from the political leanings of its workforce. Federal campaign finance records indicate that between 2015 and 2020, over 550 CDC employees made more than 8,000 political contributions, with only five directed to Republican candidates or political action committees, suggesting a pronounced left-leaning ideological skew among staff. This partisan imbalance, while not unique to the CDC, has been argued to influence research priorities and public messaging, favoring progressive public health frames such as equity-focused interventions over neutral epidemiological analysis. Critics, including those from the Journal of American Physicians and Surgeons, contend this contributes to systemic biases, compounded by the agency's acceptance of private donations since 1983, which can introduce conflicts misaligned with core scientific objectivity. Political influence on CDC operations has manifested across administrations, often through pressure on guidance and data interpretation. During the Trump administration, CDC leaders reported interference in COVID-19 messaging, such as demands to align school reopening recommendations with administration goals, leading to revised testing criteria that downplayed asymptomatic spread. Conversely, under the Biden administration, the CDC issued a nationwide eviction moratorium in August 2021, extending prior orders without explicit congressional authorization, which the Supreme Court invalidated in a 6-3 ruling as exceeding statutory authority under the Public Health Service Act. Such episodes illustrate how executive priorities can shape agency actions, eroding perceptions of independence; for instance, early CDC dismissal of the COVID-19 lab-leak hypothesis as implausible aligned with prevailing institutional narratives but shifted as evidence mounted, raising questions of politicized caution around U.S.-funded gain-of-function research. Overreach allegations center on the CDC's expansion beyond infectious disease control into social policy domains, a phenomenon termed "mission creep." Originally established in 1946 as the Communicable Disease Center with a focus on malaria eradication, the agency has grown to a $10 billion-plus budget addressing chronic conditions, lifestyle factors, and non-health issues like firearm violence, often without legislative mandate. In the 1990s, CDC-funded gun research was criticized for overt advocacy of restrictions, prompting the Dickey Amendment's restrictions on advocacy-linked studies; post-2019 clarifications allowing data collection have led to framing gun violence as a "public health crisis," including tenuous links to climate-driven heat increasing aggression, viewed by detractors as ideological overextension into Second Amendment debates. This broadening has diverted resources from core functions, as evidenced by the agency's opioid prescribing guidelines, which imposed uniform limits despite heterogeneous patient needs, contributing to undertreatment claims without robust randomized trial support. Such expansions, critics argue, reflect unelected bureaucrats supplanting legislative processes, fostering dependency on administrative fiat over evidence-based boundaries.

Erosion of Public Trust and Operational Failures

Public trust in the Centers for Disease Control and Prevention (CDC) has declined markedly since the onset of the COVID-19 pandemic, with surveys documenting drops from 82% high confidence in February 2020 to 56% by June 2025 among U.S. adults. This erosion is particularly pronounced along partisan lines, as Republican trust fell from 90% in March 2020 to 40% by September 2023, while overall confidence stood at 64% in September 2025, down from 72% the prior year. Longitudinal data from May to October 2020 further confirm a statistically significant decrease in CDC trust, contrasting with gains in trust for agencies like the U.S. Postal Service and Federal Emergency Management Agency. Operational failures during the COVID-19 response contributed substantially to this loss of confidence, including the agency's initial inability to distribute functional diagnostic test kits due to internal control weaknesses in verification processes, as identified in a root cause analysis. CDC Director Rochelle Walensky acknowledged in August 2022 that the agency bore responsibility for "pretty dramatic, pretty public mistakes" in testing, data collection, and communications, prompting an internal reorganization. Data practices were hampered by gaps, inconsistent definitions, ambiguous timing, and reliance on non-governmental sources to fill federal tracking voids, undermining real-time dissemination to states and the public. An analysis documented 25 statistical and numerical errors in CDC reporting, with 20 exaggerating pandemic severity, such as miscalculations in case fatality rates and hospitalization data. Pre-pandemic precedents, such as the 2016 CDC opioid prescribing guidelines, also fueled criticisms of operational shortcomings; intended to reduce overprescribing amid rising overdose deaths, the recommendations were widely misinterpreted as rigid dose limits, leading to abrupt patient tapers, increased withdrawal risks, and policy backlash without adequate transition guidance. These incidents, compounded by frequent guidance reversals—such as on masking, school reopenings, and booster efficacy—reinforced perceptions of inconsistency and overreach, with trust in CDC vaccine information falling to 50% by October 2025 from 63% in 2023. Congressional oversight in October 2025 highlighted how such failures stemmed from longstanding agency issues, including siloed operations and resistance to transparency.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.